
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4BB3C8AF430B305BB3C00226FB030.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="discovernano">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Discover Nano">
<meta name="citation_title" content="Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates">
<meta name="citation_author" content="Tanu Dixit">
<meta name="citation_author_institution" content="Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India">
<meta name="citation_author" content="Annamraju Aswini">
<meta name="citation_author_institution" content="Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India">
<meta name="citation_author_institution" content="Serum Institute of India Private Limited, Pune, India">
<meta name="citation_author" content="Harshal Nikam">
<meta name="citation_author_institution" content="Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India">
<meta name="citation_author_institution" content="Serum Institute of India Private Limited, Pune, India">
<meta name="citation_author" content="Anuradha Vaidya">
<meta name="citation_author_institution" content="Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India">
<meta name="citation_author" content="Selvan Ravindran">
<meta name="citation_author_institution" content="Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India">
<meta name="citation_publication_date" content="2025 Aug 18">
<meta name="citation_volume" content="20">
<meta name="citation_issue" content="1">
<meta name="citation_firstpage" content="139">
<meta name="citation_doi" content="10.1186/s11671-025-04303-w">
<meta name="citation_pmid" content="40824329">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/pdf/11671_2025_Article_4303.pdf">
<meta name="description" content="Antibody-drug conjugates (ADCs) and antibody-conjugated nanoparticles (ACNPs) are targeted therapies achieved by combining monoclonal antibodies (mAbs) with cytotoxic payloads or nanocarriers. ADCs consist of mAbs conjugated to the cytotoxic ...">
<meta name="og:title" content="Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Antibody-drug conjugates (ADCs) and antibody-conjugated nanoparticles (ACNPs) are targeted therapies achieved by combining monoclonal antibodies (mAbs) with cytotoxic payloads or nanocarriers. ADCs consist of mAbs conjugated to the cytotoxic ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12361037">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s11671-025-04303-w"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/11671_2025_Article_4303.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361037%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12361037/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12361037/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-discovernano.png" alt="Discover Nano logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Discover Nano" title="Link to Discover Nano" shape="default" href="https://doi.org/10.1186/s11671-025-04303-w" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Discov Nano</button></div>. 2025 Aug 18;20(1):139. doi: <a href="https://doi.org/10.1186/s11671-025-04303-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s11671-025-04303-w</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Discov%20Nano%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Discov%20Nano%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Discov%20Nano%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Discov%20Nano%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dixit%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Tanu Dixit</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Tanu Dixit</span></h3>
<div class="p">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dixit%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tanu Dixit</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aswini%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Annamraju Aswini</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Annamraju Aswini</span></h3>
<div class="p">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div class="p">
<sup>2</sup>Serum Institute of India Private Limited, Pune, India </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aswini%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Annamraju Aswini</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nikam%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Harshal Nikam</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Harshal Nikam</span></h3>
<div class="p">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div class="p">
<sup>2</sup>Serum Institute of India Private Limited, Pune, India </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nikam%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Harshal Nikam</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaidya%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Anuradha Vaidya</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Anuradha Vaidya</span></h3>
<div class="p">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaidya%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anuradha Vaidya</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravindran%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Selvan Ravindran</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Selvan Ravindran</span></h3>
<div class="p">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravindran%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Selvan Ravindran</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup> Faculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412 115 India </div>
<div id="Aff2">
<sup>2</sup>Serum Institute of India Private Limited, Pune, India </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 24; Accepted 2025 Jul 3; Collection date 2025 Dec.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12361037  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40824329/" class="usa-link">40824329</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Antibody-drug conjugates (ADCs) and antibody-conjugated nanoparticles (ACNPs) are targeted therapies achieved by combining monoclonal antibodies (mAbs) with cytotoxic payloads or nanocarriers. ADCs consist of mAbs conjugated to the cytotoxic payloads via a linker, thus enabling tumor-specific delivery and reducing systemic toxicity. ACNPs add to this targeted therapeutic window by using nanoparticles. This conjugation promotes controlled drug release, higher drug-to-antibody ratios (DAR), and reduced off-target effects. ADCs exhibit precision in cell killing but face limitations such as antigen heterogeneity and Fc-mediated sequestration, whereas ACNPs enhance payload capacity and tumor penetration through their tunable physicochemical properties. ACNPs also facilitate multivalent binding by functionalizing multiple antibody molecules on their surface, improving target cell recognition and binding strength. Recent advancements include 14 FDA-approved ADCs and ACNPs in Phase I/II trials. A critical analysis of synthesis methods reveals that site-specific conjugation techniques enhance batch consistency, while characterization technologies, such as SEC-HPLC, LC-MS/MS, and SPR, address challenges related to DAR quantification and aggregation. Linker chemistry innovations, such as PEGylated maleimides balancing hydrophilicity and stability, are highlighted alongside emerging payloads. Despite progress, both platforms face translational hurdles: ADCs contend with manufacturing complexity and resistance mechanisms, while ACNPs require standardized in vitro models to predict in vivo behavior. This review emphasizes the significance of comparative efficacy studies and strategies for optimizing antibody density and orientation on nanoparticles. Together, these insights connect the gaps between synthesis, characterization, and therapeutic outcomes, steering the future development of targeted bioconjugates.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Bioconjugates, Therapeutics targeted delivery system, Characterization techniques, Antibody drug conjugates</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">A method to develop monoclonal antibodies (mAbs) was developed in 1975, opening the door to cancer cell-specific therapy [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Now, mAb-mediated therapies are widely accepted, with almost 119 mAbs classified as drugs, and more are getting approval [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Treatments for many disorders, including transplantation, cancer, cardiovascular, autoimmune, and infectious diseases, now frequently include the therapeutic use of mAbs due to their elevated therapeutic efficacy and insignificant side effects [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Technological advancement has made it possible to synthesize antibodies (Abs) with altered molecular properties, such as molecular size, affinity, and specificity. By substituting the murine sequences for their human equivalent, the antigenicity restriction of murine mAb was removed, enabling the synthesis of chimeric and humanized therapeutic mAbs [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. However, due to their less potent lethality, mAbs are frequently insufficient to treat a particular disease independently [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>], and hence, to boost their therapeutic effects, researchers are conjugating them with cytotoxic medicines and nanoparticles (NPs), most commonly named ADC; Antibody-drug conjugates and ACNPs; Antibody conjugated nanoparticles) as a new concept.</p>
<p id="Par3">ADC comprises a mAb that has been explicitly conjugated to therapeutic agents using a linker molecule [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. When a monoclonal antibody binds to specific proteins or receptors in a particular cell type, the associated medication enters, kills the target cells, and leaves the remaining cells unaffected, which may reduce dose-limiting toxicities while enhancing therapeutic effects [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Despite their sophisticated designs, antibody-drug conjugates (ADCs) face several challenges, such as limited penetration into solid tumors, toxicity, and the development of resistance mechanisms [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Also, sequestration at off-target locations may be attributed to ADC binding to the neonatal Fc receptor (FcRn), which is present in a range of non-tumor organs [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Though they struggle with solid tumor penetration and resistance mechanisms, ADCs can still bind to normal tissues. This occurs because the Fc domain interacts with the neonatal Fc receptor, leading to sequestration in non-tumor areas, potential off-target effects, and heightened immunogenicity. To overcome the aforementioned drawbacks, the development of ADCs, including new antibody forms, cytotoxic compounds, antigenic targets, and novel site-specific bioconjugation techniques, has been studied by many researchers [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>].</p>
<p id="Par4">Recently, ACNPs have been successfully assessed in clinical trials, following the footsteps of ADCs [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Nanomedicine has received significant attention as an inventive formulation-based strategy to enhance the biological availability of medicinal compounds. The characteristics of the NPs, including their excellent surface-to-volume ratio enabling magnificent drug loading capacity and the mAb’s ability to recognize antigens precisely and selectively, are combined during the conjugation process, which may have the dual benefits of improved cellular absorption and significant intracellular stability [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. Although several ADCs have received FDA approval for treating several diseases, FDA-approved ACNPs are still missing [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Before they may be more widely used, several obstacles need to be cleared. This review discusses mAbs, ADCs, ACNPs, various conjugation strategies, characterization techniques, and current status and bottlenecks for both concepts.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Monoclonal abs (mAbs)</h2>
<p id="Par5">Therapeutic mAbs have evolved from research tools to effective human therapeutics over the past three decades. They first accessed the clinic over 25 years ago and brought a therapeutic revolution because of their ability to show affinity to specific molecular components [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Many mAbs have been approved for long-term diseases, autoimmune disorders, and other areas such as oncology. For introducing hybridoma technology and enabling the applications of numerous mAbs targeted against particular targets, researchers Cesar Milstein and George Kohler received the Nobel Prize in Medicine or Physiology in 1984 [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. The mAbs are proteins secreted by hybridoma cells, which are fusions of B cells and myeloma cells, as illustrated in Fig. <a href="#Fig1" class="usa-link">1</a>. These hybridomas can be stored indefinitely because they can be frozen and thawed, which implies the availability of an endless supply of homogeneous and specific mAbs [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. Initially, this method was primarily used to create murine mAbs (derived solely from mice), such as tositumomab [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. As these murine mAbs induced significant immunological responses in humans, particularly after periodic injection, more mAb types were developed using additional engineering and recombinant technologies, for example, chimeric mAbs, including rituximab and cetuximab which are synthesized by combining V<sub>L</sub> and V<sub>H</sub> from murine origins with CH<sub>1</sub>, CH<sub>2,</sub> and CH<sub>3</sub> from human origins. The humanized mAbs trastuzumab and alemtuzumab were synthesized by substituting the complementarity-determining portion of the murine origin with the human origin, further reducing the murine parts [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. When deciding which mAbs to use, factors such as their method of manufacture, effector function, and transport to their target tissue should be considered. Concerns about mAbs’ commercial viability and the high administration expense may be partly to blame for their lack of overall economic success and first infusion-related reactions such as fever. For instance, alemtuzumab costs about £37,000 for a year’s treatment for leukaemia [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Therefore, to make mAbs more commercially viable, difficulties related to administrative costs, the requirement for enhanced efficacy, and minimizing side effects can be addressed. Long-term mAbs commercialization will also be influenced by other variables such as patient compliance, quality control, pharmaceutical industry competition, and financial incentives for developing mAbs. Therefore, research revealed the potential of conjugating mAbs with effector molecules such as cytotoxic medicines, NPs, enzymes, bacterial toxins, etc., to open up new possibilities for utilizing their specific binding property for enhanced drug delivery.</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361037_11671_2025_4303_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51a/12361037/fb2f59c8c3a6/11671_2025_4303_Fig1_HTML.jpg" loading="lazy" id="d33e278" height="803" width="708" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic representation of the synthesis of mAbs; Monoclonal antibodies along with systematic representation of <em>ADC</em> Antibody Drug conjugates and <em>ACNP</em> Antibody conjugated nanoparticles</p></figcaption></figure><section id="Sec3"><h3 class="pmc_sec_title">Antibody-drug conjugates (ADCs)</h3>
<p id="Par6">Antibody-drug conjugates (ADCs) are designed by conjugating humanized/human mAbs with cytotoxic agents by chemical linkers to selectively target and kill cancer cells and minimize the effect on healthy cells [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Their development has led to overcoming the limitations of conventional chemotherapy by improving specificity, reducing systemic toxicity, and increasing efficacy [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. The main benefit of ADCs compared to chemotherapy is their capacity to specifically target cancer cells without affecting normal ones [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. This minimizes collateral damage, improves patient tolerance, and enables highly effective cytotoxic drugs that would typically be too toxic. Additionally, the efficient drug delivery feature of ADCs has led to potential healthcare cost reduction by reducing hospital stays, requiring comparatively lesser doses, supportive treatments, etc [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. The concept of selective targeting was first proposed by Paul Ehrlich in 1913, in which he used the term magic bullet to target either pathogenic microbial or cancerous cells selectively. However, the first successful ADC was reported in 1983, which showed promising outcomes. The development of ADC was a result of the development of successful chemotherapy in the 1940s and mAbs in the 1970s. The first ADC, Mylotarg (gemtuzumab ozogamicin), was introduced in 2000 for acute myeloid leukemia (AML) but was later withdrawn due to safety concerns [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. It was reapproved in 2017 with adjusted dosing. Since then, ADCs like Adcetris (brentuximab vedotin) for lymphoma and Kadcyla (trastuzumab emtansine) for HER2-positive breast cancer have gained approval, reflecting progress in ADC technology [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>, <a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>].</p>
<p id="Par7">ADCs consist of mAbs covalently linked to cytotoxic agents via chemical linkers, ensuring targeted cancer therapy. For this, either humanized mAbs or of human origin are preferred for their specificity, higher half-life, and low immunogenicity. ADCs, after binding to the cancer cell antigens, are internalized via endocytosis and then released the drug inside the lysosome. These drugs disrupt DNA, microtubules, or enzymatic processes, leading to cancer cell death. Most ADCs use microtubule inhibitors or DNA-damaging agents. The release mechanism varies as per the property of the linker used; while some are enzymatically cleaved, others are disrupted by the altered pH.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Key components of ADCs and their selection</h3>
<section id="Sec5"><h4 class="pmc_sec_title">Therapeutic target</h4>
<p id="Par9">Unique markers present in the tumor cells but not in normal cells are considered suitable therapeutic targets. Common targets include CD33 (gemtuzumab ozogamicin) [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>], CD30 (brentuximab vedotin) [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>], HER2 (trastuzumab) [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], and Trop-2 (sacituzumab govitecan) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. The antigen must also be internalized after antibody binding to ensure proper delivery of the cytotoxic payload. The density of antigen expression influences ADC potency, increases drug uptake, improving treatment response [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p>
<p id="Par10">The antigen must also remain stable, with minimal shedding into the bloodstream. If an antigen is highly shed, it can bind to ADCs before they reach their target, reducing therapeutic effectiveness. Careful selection of an antigen ensures effective tumor targeting with minimal side effects [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>].</p></section><section id="Sec6"><h4 class="pmc_sec_title">Monoclonal antibody</h4>
<p id="Par11">Because of their affinity for specific targets, mAbs show the potential to reduce the limitations of existing treatment regimes, including ineffectiveness, side effects, poor pharmacokinetics, off-target toxicity, etc. As mAbs readily conjugate to drugs and nanoparticulate drug delivery systems, they are being studied for directing drugs or delivery systems to targeted sites for better selectivity and enhanced drug delivery. For instance, an ADC called besponsa utilizes the targeting ability of a humanized mAb specific to CD22 protein expressed by leukemia cells to deliver a drug called ozogamicin, which showed better treatment efficacy than using only the drug. More such examples have been discussed in Table <a href="#Tab1" class="usa-link">1</a>.</p>
<section class="tw xbox font-sm" id="Tab1"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>FDA-approved antibody-drug conjugates</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Sr. no.</th>
<th align="left" colspan="1" rowspan="1">Trade name</th>
<th align="left" colspan="1" rowspan="1">Generic name</th>
<th align="left" colspan="1" rowspan="1">mAbs</th>
<th align="left" colspan="1" rowspan="1">Cytotoxic payload</th>
<th align="left" colspan="1" rowspan="1">Payload mechanism</th>
<th align="left" colspan="1" rowspan="1">Linker</th>
<th align="left" colspan="1" rowspan="1">Average DAR</th>
<th align="left" colspan="1" rowspan="1">Target</th>
<th align="left" colspan="1" rowspan="1">Condition</th>
<th align="left" colspan="1" rowspan="1">Approval year</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Mylotarg™</td>
<td align="left" colspan="1" rowspan="1">Gemtuzumab ozogamicin [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]</td>
<td align="left" colspan="1" rowspan="1">Recombinant humanized IgG4 anti-CD33</td>
<td align="left" colspan="1" rowspan="1">Antibiotic derivative Calich-DMH</td>
<td align="left" colspan="1" rowspan="1">DNA cleavage</td>
<td align="left" colspan="1" rowspan="1">Acid cleavable (Bifunctional AcBut linker)</td>
<td align="left" colspan="1" rowspan="1">2–3</td>
<td align="left" colspan="1" rowspan="1">CD33</td>
<td align="left" colspan="1" rowspan="1">Acute myeloid leukemia</td>
<td align="left" colspan="1" rowspan="1">Withdrawn in 2010, reapproved in 2017</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Adcetris®</td>
<td align="left" colspan="1" rowspan="1">Brentuximab vedotin [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]</td>
<td align="left" colspan="1" rowspan="1">Recombinant chimeric IgG1anti-CD30</td>
<td align="left" colspan="1" rowspan="1">Anti-microtubule agent MMAE</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Enzyme Protease-cleavable (Thiolactone maleimidocaproyl spacer, dipeptide, and self-immolative, or PABC, spacer)</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">CD30</td>
<td align="left" colspan="1" rowspan="1">Hodgkin’s lymphoma and ALCL, PTCL, sALCL, pcALCL, LBCL</td>
<td align="left" colspan="1" rowspan="1">2011</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Kadcyla®</td>
<td align="left" colspan="1" rowspan="1">Trastuzumab emtansine [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized anti-HER2 IgG1, Trastuzumab</td>
<td align="left" colspan="1" rowspan="1">Maytansinoid DM1</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Non-cleavable Thioether linker MCC</td>
<td align="left" colspan="1" rowspan="1">3.5</td>
<td align="left" colspan="1" rowspan="1">HER2</td>
<td align="left" colspan="1" rowspan="1">HER2-positive metastatic breast cancer</td>
<td align="left" colspan="1" rowspan="1">2013</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Besponsa®</td>
<td align="left" colspan="1" rowspan="1">Inotuzumab ozogamicin [<a href="#CR24" class="usa-link" aria-describedby="CR24">27</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized monoclonal IgG4 antibody (G544)</td>
<td align="left" colspan="1" rowspan="1">Calich-DMH</td>
<td align="left" colspan="1" rowspan="1">DNA cleavage</td>
<td align="left" colspan="1" rowspan="1">Butanoic Acid-cleavable linker</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">CD22</td>
<td align="left" colspan="1" rowspan="1">Acute lymphoblastic leukemia</td>
<td align="left" colspan="1" rowspan="1">2017</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Lumoxiti®</td>
<td align="left" colspan="1" rowspan="1">Moxetumomab pasudotox [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]</td>
<td align="left" colspan="1" rowspan="1">Fv fragment of recombinant murine (anti-CD22)</td>
<td align="left" colspan="1" rowspan="1">Pseudomonas exotoxin A (PE38)</td>
<td align="left" colspan="1" rowspan="1">Induction of apoptosis</td>
<td align="left" colspan="1" rowspan="1">(Fv fragment of an anti-CD22 monoclonal antibody is fused with PE38)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">CD22</td>
<td align="left" colspan="1" rowspan="1">Adults with relapsed or refractory HCL</td>
<td align="left" colspan="1" rowspan="1">
<p>2018</p>
<p>Discontinued in 2023</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">Polivy®</td>
<td align="left" colspan="1" rowspan="1">Polatuzumab vedotin [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized IgG1</td>
<td align="left" colspan="1" rowspan="1">MMAE</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Enzyme Protease-cleavable (Thiolactone maleimidocaproyl spacer, dipeptide, and self-immolative, or PABC, spacer)</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">CD79b</td>
<td align="left" colspan="1" rowspan="1">DLBCL</td>
<td align="left" colspan="1" rowspan="1">2019</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">Padcev®</td>
<td align="left" colspan="1" rowspan="1">Enfortumab vedotin [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized IgG1</td>
<td align="left" colspan="1" rowspan="1">MMAE</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Protease-cleavable (Maleimidocaproyl valine-citrulline linker)</td>
<td align="left" colspan="1" rowspan="1">3.8</td>
<td align="left" colspan="1" rowspan="1">Nectin-4</td>
<td align="left" colspan="1" rowspan="1">Metastatic Urothelial Cancer</td>
<td align="left" colspan="1" rowspan="1">2019</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">Enhertu®</td>
<td align="left" colspan="1" rowspan="1">Fam-trastuzumab deruxtecan-nxki [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</td>
<td align="left" colspan="1" rowspan="1">Trastuzumab</td>
<td align="left" colspan="1" rowspan="1">Deruxtecan</td>
<td align="left" colspan="1" rowspan="1">Topoisomerase inhibitor</td>
<td align="left" colspan="1" rowspan="1">Tetrapeptide-based cleavable linker</td>
<td align="left" colspan="1" rowspan="1">7.7</td>
<td align="left" colspan="1" rowspan="1">HER2</td>
<td align="left" colspan="1" rowspan="1">(1) Unresectable or metastatic HER2-positive breast cancer (2) NSCLC</td>
<td align="left" colspan="1" rowspan="1">2019, 2020</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">Trodelvy®</td>
<td align="left" colspan="1" rowspan="1">Sacituzumab govitecan-hziy [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized hRS7 IgG1κ antibody</td>
<td align="left" colspan="1" rowspan="1">SN-38 (Govitecan)</td>
<td align="left" colspan="1" rowspan="1">Topoisomerase I inhibitor</td>
<td align="left" colspan="1" rowspan="1">Hydrolyzable ‘CLA’ linker</td>
<td align="left" colspan="1" rowspan="1">7.6</td>
<td align="left" colspan="1" rowspan="1">Trop-2</td>
<td align="left" colspan="1" rowspan="1">Metastatic triple-negative breast cancer, Metastatic Urothelial cancer</td>
<td align="left" colspan="1" rowspan="1">
<p>Urothelial carcinoma: 2021</p>
<p>HER2- breast cancer: 2023</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">Blenrep®</td>
<td align="left" colspan="1" rowspan="1">Belantamab mafodotin-blmf [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]</td>
<td align="left" colspan="1" rowspan="1">Afucosylated Humanized IgG1 mAb</td>
<td align="left" colspan="1" rowspan="1">MMAF</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Protease-resistant maleimidocaproyl linker</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">BCMA</td>
<td align="left" colspan="1" rowspan="1">Multiple myeloma</td>
<td align="left" colspan="1" rowspan="1">
<p>2020</p>
<p>withdrawn in 2023</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">Zynlonta™</td>
<td align="left" colspan="1" rowspan="1">Loncastuximab tesirine-lpyl [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]</td>
<td align="left" colspan="1" rowspan="1">Humanized IgG1κ mAb</td>
<td align="left" colspan="1" rowspan="1">SG3199 pyrrolobenzodiazepine (PBD)</td>
<td align="left" colspan="1" rowspan="1">Create cytotoxic inter-strand DNA cross-links</td>
<td align="left" colspan="1" rowspan="1">Protease-cleavable valine-alanine linker</td>
<td align="left" colspan="1" rowspan="1">2.3</td>
<td align="left" colspan="1" rowspan="1">CD19</td>
<td align="left" colspan="1" rowspan="1">Relapsed or Refractory Diffuse Large B-cell lymphoma</td>
<td align="left" colspan="1" rowspan="1">2021</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">Tivdak®</td>
<td align="left" colspan="1" rowspan="1">Tisotumab vedotin-tftv [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</td>
<td align="left" colspan="1" rowspan="1">Human anti-TF IgG1κ antibody</td>
<td align="left" colspan="1" rowspan="1">MMAE</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Protease-cleavable (Mc-vc-PABC linker)</td>
<td align="left" colspan="1" rowspan="1">4.0</td>
<td align="left" colspan="1" rowspan="1">Tissue factor (TF-011)</td>
<td align="left" colspan="1" rowspan="1">Recurrent or metastatic cervical cancer</td>
<td align="left" colspan="1" rowspan="1">2021</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">Elahere™</td>
<td align="left" colspan="1" rowspan="1">mirvetuximab soravtansine-gynx [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">FRα-directed mAb</td>
<td align="left" colspan="1" rowspan="1">DM4 (Maytansine derivative) Payload</td>
<td align="left" colspan="1" rowspan="1">Microtubule inhibitor</td>
<td align="left" colspan="1" rowspan="1">Sulfo-SPDB (cleavable, 1-(2,5-dioxopyrrolidin-1-yl)-oxo-4-(pyridin-2-yldisulfanyl) butane-2-sulfonic acid)</td>
<td align="left" colspan="1" rowspan="1">3.4</td>
<td align="left" colspan="1" rowspan="1">FRα</td>
<td align="left" colspan="1" rowspan="1">Ovarian cancer, fallopian tube cancer, peritoneal cancer</td>
<td align="left" colspan="1" rowspan="1">2022</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p18"><p><em>DAR</em> drug antibody ratio, <em>Calich-DMH</em> N-acetyl gamma Calicheamicin dimethyl hydrazide, <em>HER2</em> human epidermal growth factor 2, <em>DM1</em> mertansine, <em>MCC</em> 4-[N-maleimidomethyl]-cyclohexane-1-carbonyl, <em>ALL</em> acute lymphoblastic leukemia, <em>ALCL</em> anaplastic large cell lymphoma, <em>PTCL CD30-Expressing peripheral T-Cell Lymphomas</em>,<em> sALCL systemic anaplastic large cell Lymphoma</em>,<em> PcALCL primary cutaneous anaplastic large cell Lymphoma</em>,<em> LBCL relapsed or refractory large B-Cell Lymphoma</em>,<em> HCL</em> hairy cell leukemia, <em>BCMA</em> B cell maturation antigen, <em>DLBCL</em> diffuse large B-cell lymphoma <em>Trop-2</em> trophoblast cell surface Antigen-2, <em>IgG</em> Immunoglobulin G, <em>NSCLC</em> metastatic <em>HER2</em> mutated non-small cell lung cancer, <em>MMAF</em> monomethyl auristatin F, <em>N/A</em> not available sources, <em>MMAE</em> monomethyl auristatin E, Sulfo-SPDB N-succinimidyl 4-(2-pyridyldithio)butanoate, sulfonated</p></div></div></section><p id="Par12">The monoclonal antibody moiety provides specificity for tumor targeting. Humanized or fully human monoclonal antibodies (mAbs) reduce immunogenic response and increase circulation time [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. Using a high-affinity, stable antibody is critical as this will ensure a long half-life and thus allow sufficient time for tumor targeting and internalization [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. To achieve maximum therapeutic effects, Fc receptor modifications may be incorporated to influence immune-mediated effects such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p>
<p id="Par13">Recent developments in recombinant antibody manufacturing have been instrumental in upgrading manufacturing methods and producing high-quality and effective therapeutic antibodies [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. For example, the identification of bispecific antibodies—more particularly, those aiming to target simultaneously interleukin-4 (IL-4) and interleukin-13 (IL-13)—has revealed the potential hidden in dual-targeting strategies for modulating the immune system [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. These improvements underscore the role of judicious antibody selection, as in trastuzumab and brentuximab vedotin, increasing the effectiveness of antibody-drug conjugates (ADCs) by offering both specificity and good interaction with tumor cells [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>].</p>
<p id="Par14">mAbs play a dual role as targeting moieties as well as carriers in ADCs. They bind to the tumor-associated antigens like HER2 or CD30 with great specificity, thus promoting selective delivery of cytotoxic payloads to only cancer cells [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. This minimizes off-target effects and improves the therapeutic window. Additionally, mAbs offer excellent stability for conjugation with cytotoxic drugs and act as an efficient carrier for site-specific transport of cytotoxic payloads [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>].</p></section><section id="Sec7"><h4 class="pmc_sec_title">Linkers</h4>
<p id="Par15">Linkers control drug release and contribute to ADC stability [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. They must remain intact in circulation but allow drug release once inside the target cell. Linkers fall into two categories: cleavable and non-cleavable [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Linker configuration (cleavable or non-cleavable) impacts ADC stability and payload release. Hydrophilic linkers, such as PEGylated linkers, balance payload hydrophobicity, allowing higher drug loading while maintaining stability [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Cleavable linkers (e.g., in brentuximab vedotin) respond to pH or enzymatic triggers, while non-cleavable linkers (e.g., in trastuzumab emtansine) enhance circulation stability [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>].</p>
<p id="Par16">Cleavable linkers in brentuximab vedotin and gemtuzumab ozogamicin respond to pH changes, enzymatic activity, or redox conditions to release the drug in the tumor cell [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Non-cleavable linkers, such as those in trastuzumab emtansine, require degradation of the entire antibody to release the payload. Cleavable linkers provide faster drug release but may have stability issues, leading to off-target toxicity [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. Non-cleavable linkers improve circulation stability but require more processing inside the cell for drug activation. The choice of linker affects ADC performance, influencing both safety and therapeutic efficiency [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. Furthermore, the linker structure also plays an important role in controlling the hydrophobic properties of the attached drug, thereby influencing the overall stability and efficacy of ADCs. The linker also affects drug loading capacity because a well-designed linker with balanced hydrophilic properties supports higher drug loading without affecting the physiological activity of the conjugate.</p></section><section id="Sec8"><h4 class="pmc_sec_title">Therapeutic Agent</h4>
<p id="Par17">The cytotoxic payload is the active drug that kills tumor cells [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Common payloads include microtubule inhibitors (monomethyl auristatin E in brentuximab vedotin, maytansinoids in trastuzumab emtansine) and DNA-damaging agents (calicheamicins in gemtuzumab ozogamicin, topoisomerase inhibitors in sacituzumab govitecan) [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. These drugs are too toxic for systemic use but become effective when delivered selectively through an ADC. The potency of the payload must be carefully balanced. It must be strong enough to eliminate tumor cells but not so aggressive that it causes unintended toxicity. Researchers are now exploring new classes of payloads, such as immune-modulating agents and metabolic inhibitors, to improve ADC function and reduce resistance. Advancements in conjugation technology ensure precise drug-to-antibody ratios, enhancing therapeutic effects while maintaining safety. Beyond traditional payloads like microtubule inhibitors and DNA-damaging agents, emerging ADC designs include bispecific ADCs targeting multiple antigens, probody–drug conjugates for tumor-specific activation, protein-degrader ADCs for targeted protein degradation, and dual-drug ADCs for synergistic effects. These innovations aim to enhance efficacy and overcome resistance [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>].</p>
<p id="Par18">In contrast, conjugation with ADC leaves the cytotoxic drug invisible in the bloodstream, permitting direct delivery to the target cells and minimizing the toxicity of these very potent medications. Currently, many cytotoxic medicines with a new mechanism of action are used in ADC designs. For instance, small-molecule immunomodulators (SMIMs), also known as immune-stimulating antibody conjugates (ISACs), have recently been used to develop innovative ADC medicines [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. In ISACs, the effectiveness of the small molecule-based regulation of the non-specific and specific immune system is combined with the accuracy of Ab-navigated targeting [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Further, the drug antibody ratio (DAR) assessment is also essential for assessing the efficacy of ADCs as less drug loading can reduce the strength, and high drug loading can impact the toxicity and pharmacokinetics [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]. Other ADC variables, such as the binding site and whether conjugation is on light or heavy chains, significantly affect DAR as low drug loading reduces drug strength and high DAR value increases drug potency.</p></section></section><section id="Sec9"><h3 class="pmc_sec_title">Mechanism of action of ADCs</h3>
<p id="Par19">ADCs can destroy target cells precisely as they play the specified target function and effectual killing effect, thus improving the pharmaceutical window and minimizing off-target toxicity [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>, <a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. The ADC is endocytosed by cells (via clathrin or caveolae-mediated endocytosis) and forms an early endosome, which matures into late endosomes and then merges with lysosomes once the mAb of the ADC has been attached to the target antigens mainly expressed on the target cells [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. Cell apoptosis or death is eventually caused by the release of the cytotoxic payloads in the lysosomes via chemical or enzyme-mediated mechanisms that target DNA or microtubules. When a transmembrane or permeable payload is released, the bystander effect (killing of adjacent antigen-negative cells or the ability of the released cytotoxic drug to spread from the target cell and destroy nearby tumor cells that are not the target particularly helpful when treating cancers with variable antigen expression) may also be induced, increasing the effectiveness of ADC [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. Additionally, the tumor microenvironment may change due to these medications’ bystander effect, which could ultimately strengthen the killing power of ADCs. For instance, in Mylotarg®, calicheamicin (cytotoxic payload) was conjugated to gemtuzumab (IgG4) via a chemical linker containing a hydrazone bond; calicheamicin can be released after the hydrazone bond has been internalized and hydrolyzed in the acidic endosomal environment, it is subsequently reduced by glutathione to the active form which binds to the minor grooves of DNA and undergoes Bergman cyclization, creating a highly reactive diradical that results in double-strand breaks specific to a sequence [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. Adcentris is another example, which bioconjugates dolastatin to the cysteine residue of anti-CD30 Ig1. The FDA granted Adcentris a license to treat anaplastic large-cell lymphoma in 2011. The interchain disulfide bridges were only minimally and partially reduced prior to the anti-CD30 mAb being bio-conjugated to a cleavable heterobifunctional maleimide linker [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. Following the dissolution of cleavable linkers and internalization of ADC, MMAE is released, which kills the target cell and diffuses across the plasma membrane to reach and destroy neighboring cells. This phenomenon is referred to as the “bystander effect” [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>] (Fig. <a href="#Fig2" class="usa-link">2</a>). </p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361037_11671_2025_4303_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51a/12361037/1cfaea09d972/11671_2025_4303_Fig2_HTML.jpg" loading="lazy" id="d33e954" height="386" width="708" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanism of the action of ADCs</p></figcaption></figure></section><section id="Sec10"><h3 class="pmc_sec_title">Characterization methods employed for ADCs</h3>
<p id="Par20">The DAR and dispersity are the major emphases of the analytical techniques currently being utilized to analyze ADCs [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. Differential scanning calorimetry (DSC) is used to quantify changes in high-order structure, dynamic light scattering (DLS) measures aggregation, MALDI (Matrix-assisted laser desorption ionization) determines DAR, and immunoassays look for disturbed Fc region binding, among other approaches, in the routine evaluation of ADC characteristics [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Various characterization tools for antibody-drug conjugates are summarized in Fig. <a href="#Fig3" class="usa-link">3</a>. The merits and demerits of each of the characterization techniques are presented in Table <a href="#Tab2" class="usa-link">2</a>.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361037_11671_2025_4303_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51a/12361037/83b7a1fadcf1/11671_2025_4303_Fig3_HTML.jpg" loading="lazy" id="d33e982" height="748" width="708" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Various characterization tools for antibody-drug conjugates</p></figcaption></figure><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Merits and demerits of characterization techniques for ADCs</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Techniques</th>
<th align="left" colspan="1" rowspan="1">Merits</th>
<th align="left" colspan="1" rowspan="1">Demerits</th>
<th align="left" colspan="1" rowspan="1">Reference</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">UV-Visible spectroscopy</td>
<td align="left" colspan="1" rowspan="1">Simple, rapid, quantifies DAR</td>
<td align="left" colspan="1" rowspan="1">Limited by buffer interference, less specific</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HIC</td>
<td align="left" colspan="1" rowspan="1">Non-denaturing, separates intact ADCs</td>
<td align="left" colspan="1" rowspan="1">Limited resolution for heterogeneous samples</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>, <a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SEC</td>
<td align="left" colspan="1" rowspan="1">Detects aggregation, high molecular weight species</td>
<td align="left" colspan="1" rowspan="1">Poor resolution for small hydrodynamic changes</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CE</td>
<td align="left" colspan="1" rowspan="1">High resolution for charge-based separations</td>
<td align="left" colspan="1" rowspan="1">Not suitable for heterogeneous samples with minimal pI variation</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">RP-HPLC</td>
<td align="left" colspan="1" rowspan="1">Characterizes site-specific conjugates</td>
<td align="left" colspan="1" rowspan="1">Non-specific interactions with hydrophobic payloads</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mass spectrometry (MALDI/ESI)</td>
<td align="left" colspan="1" rowspan="1">High sensitivity, confirms conjugation and DAR</td>
<td align="left" colspan="1" rowspan="1">Requires salt removal, complex data interpretation</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>, <a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Multidimensional LC-MS</td>
<td align="left" colspan="1" rowspan="1">High resolving power, detailed structural analysis</td>
<td align="left" colspan="1" rowspan="1">Complex setup, time-consuming</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CE-MS</td>
<td align="left" colspan="1" rowspan="1">High selectivity, detects hydrophobic peptides</td>
<td align="left" colspan="1" rowspan="1">Limited compatibility with certain buffers</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>, <a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section id="Sec11"><h4 class="pmc_sec_title">UV-visible spectroscopy</h4>
<p id="Par22">UV-visible spectroscopy is often used to calculate DAR [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]. By comparing the absorbance of mAbs to that cytotoxic payload at 280 nm, Beer-Lambert’s law can be used to determine this molar ratio. This technique has been used to assess ADCs carrying a range of payloads, including DM1, methotrexate, and auristatin [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. It is essential to consider all potential sources of 280 nm absorbance as well as the variations in extinction coefficients brought on by various buffers.</p></section><section id="Sec12"><h4 class="pmc_sec_title">Chromatography</h4>
<p id="Par23">Based on properties unique to conjugation, linker, and payload, various chromatography methods can be utilized to resolve the ADCs. Native ADCs can be best resolved via HIC (Hydrophobic Interaction Chromatography) and CE (Capillary Electrophoresis) [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>]. SEC (Size Exclusion Chromatography) can be utilized to describe the variation in the ADC samples, especially when aggregation is expected [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. However, the non-specific synergy between the payload and the stationary phase of columns could occur due to the payload’s hydrophobicity. The hydrodynamic radius shift provided by modest drug conjugation may not be sufficient for SEC resolution. Charge-based separations like CE help characterize ADCs since drug conjugation can significantly affect the electrostatic properties of mAbs [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. Such changes in the ADC’s isoelectric point can be studied using isoelectric focusing and ion exchange chromatography [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. These techniques cannot be used on heterogeneous samples with minimal isoelectric point variations. Conventional RP-HPLC (Reverse-Phase High-Performance Liquid Chromatography), specifically with the C18 column, can be used to characterize synthetic amino acid-linked conjugates and different site-specifically linked ones [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. Specifically, HIC is suitable for characterizing intact ADCs due to the use of pH-neutral and non-denaturing salt gradients for separation [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]. Combining separation with additional tests like UV-visible and mass spectrometry significantly improves the information on ADC composition obtained by chromatography.</p></section><section id="Sec13"><h4 class="pmc_sec_title">Mass spectrometry (MS)</h4>
<p id="Par24">Mass spectrometry (MS) is now more helpful in analyzing more significant macromolecules, such as antibodies, because of advancements in ionization techniques like MALDI and ESI [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. Mass spectra can be acquired relatively quickly, but it’s crucial to eliminate salts or other excipients that might prevent protein ionization. It is common practice to use LC-MS (Liquid Chromatography coupled with MS) to boost resolution. The major shift between the only mAb and ADC can be found using MALDI-TOF MS [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. Even if MALDI-TOF is inadequate for the mass accuracy required to distinguish various species with different amounts of conjugated drugs, the analysis of the resulting peak spectra can validate conjugation and calculate the average DAR. “Charge envelopes” of multiple-charged, ionized molecules are determined using ESI-MS. This improves a variety of DAR variations’ accuracy, reliability, and resolution. Additionally, combining multiple analytical techniques, referred to as novel hyphenated methods, helps to the particulars of the ADC structure.</p></section><section id="Sec14"><h4 class="pmc_sec_title">Multidimensional LC coupled with MS</h4>
<p id="Par25">A combination of cutting-edge technologies with maximum resolving power, contemporary analytical techniques, and analysis of ADC is necessary because of its tremendous complexity. The utilization of complementary separation modes in 2D-LC, which gives excellent selectivity and resolving power, makes it an intriguing method. Additionally, since RPLC is compatible with MS and is frequently one of the chosen chromatographic modes, it is preferred to use it in the second dimension [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. For example, an SEC-RPLC-UV/MS technique was described to evaluate the non-conjugated cytotoxic payload and impurities in ADC products. SEC in the first dimension can segregate proteins, and some percentage of low molecular weight compounds are transferred to the second dimension where numerous small molecule species can be separated using the RPLC column, including linker, non-conjugated drug, linker-drug, and contaminants.</p></section><section id="Sec15"><h4 class="pmc_sec_title">Combining capillary electrophoresis with MS (CE-MS)</h4>
<p id="Par26">The rise in popularity of CE-MS for characterizing biological products such as ADCs can be ascribed to the development of CE-MS apparatus as it ameliorates the compatibilities between the two techniques. The exceptional sensitivity offered by the finest MS equipment combines with the excellent selectivity of electrophoretic separation to develop CE-MS technology [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]. For instance, the PBD dimer in an ADC coupled with a cysteine intermediate was characterized using the CZE-MS method. After being subjected to proteolytic processing, the peptide combination was examined by CZE-MS using a background electrolyte containing a small quantity of the organic solvent to improve separation selectivity. The thorough sequence coverage of the obtained results was highlighted by systematically identifying various peptides concerning their chemical makeup using the extremely hydrophobic peptides containing PBD medicine. The most common glycopeptides may also be detected. The equivalent ADC peptide combination was compared with RPLC-MS analysis to demonstrate the orthogonality of the two instrumental approaches [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>].</p></section></section></section><section id="Sec16"><h2 class="pmc_sec_title">Antibody conjugated nanoparticles (ACNPs)</h2>
<p id="Par28">When materials are in bulk form, where their physical qualities are constant over a range of sizes, they do not exhibit the particular physicochemical characteristics that NPs do, including a high surface-to-volume ratio, owing to which there is an increase in the catalytic activity of the catalyst, increased solubility, stability, etc [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. One of these formulations’ key clinical advantages is the ability to lessen the toxicity profiles of the cargo chemotherapeutical, hence increasing the pharmaceutical window for that drug [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. NPs are functional in many biomedical applications because of these characteristics. The conjugation of various moieties to NPs expands their range of applications, giving them new or improved features such as the conjugation of peptides, low molecular weight ligands, DNA, plasmids, siRNA, and other bio components [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. However, some key drawbacks include the peptides’ vulnerability to protease, high manufacturing cost, and susceptibility to enzymatic destruction of synthetic DNA or RNA, also known as aptamers. ACNPs are a recent avenue that depends on the effectiveness and potential of both ADCs and nanoscience. This new formulation makes it possible to conjugate targeted Abs to nanoparticle surfaces covalently and precisely, which is highly desired, especially for those who do not use expensive and time-consuming Ab manufacturing approaches. Two main biomedical uses for ACNPs are therapy, including tissue healing and development of tailored medication delivery, and diagnostics, including sensing, cell sorting, immunoassays, gene delivery, bioseparation, and other techniques. Targeted drug and gene delivery is the principal potential therapeutic application [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. With this overview of potential, we further describe the components, conjugation methods, and characterization methods involved in the development of ACNPs.</p>
<section id="Sec17"><h3 class="pmc_sec_title">Key components of ACNPs and their selection</h3>
<p id="Par29">The cytotoxic payloads for antibody-conjugated nanoparticles are nanoparticles with therapeutic capabilities, but the target antigen, target-specific mAb, and linker molecules stay the same as discussed for ADCs. The numerous possible uses of nanotechnology in the field of medicine may hold nanotechnology’s most significant promise. The National Institutes of Health have recognized nanoscale medical technologies as “nanomedicines” because they are promising to alter the strategies to treat and prevent diseases [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. The development of nanotechnology has made it possible to create cell-type-specified delivery systems that can more efficiently distribute biological materials and pharmaceuticals. Many different nanomaterials can be used to synthesize nanomaterial-based drug delivery systems, including polymeric NPs, lipid liposomes, emulsions, nanotubes, and self-assembled micelles, which serve as a platform for simultaneously linking other biomolecules, preserving their original biological features with little to no change [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>].</p></section><section id="Sec18"><h3 class="pmc_sec_title">ACNPs: linker and conjugation methods</h3>
<p id="Par30">Potential nanomaterial-mediated efficacy is dependent specifically on the selection of a chemical linker as it promotes the attachment and release of the cytotoxic payload at the specific subcellular area or tissue. Other essential elements include encapsulating or linking a medication or mAb to a nanomaterial. Many of the linkers and conjugation methods utilized to develop such systems have been modified versions of those used to build immunoconjugates and Ab drug conjugates. However, three typical linker types are most frequently used, and each type can be divided into groups based on how they cleave. An acidic pH can cause disulfide linkers to cleave, a reducing environment can cause hydrazone linkers to cleave, and proteases can cause peptide linkers to cleave [<a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>].</p>
<p id="Par31">There are various ways to immobilize mAbs on NPs. However, they can be segregated into two sections: non-covalent and covalent immobilizations [<a href="#CR86" class="usa-link" aria-describedby="CR86">86</a>]. The mAb is directly adsorbed onto NPs in a non-covalent attachment. The mAbs and NPs interact electrostatically and hydrophobically in this type of binding. Due to the attachment requiring a particular pH of the solution for each mAb, direct adsorption has limits. The antibody’s isoelectric point (pI) must be somewhat higher than the pH of the solution for optimal binding. Nonspecific adsorption and randomly oriented mAb adsorption on the nanoparticle surface are additional drawbacks of direct adsorption [<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>]. Numerous techniques for covalently attaching mAbs to the surface of NPs have been developed to circumvent the drawbacks of direct adsorption. Carbodiimide chemistry is the most used technique based on crosslinking carboxylic acids to primary amines by utilizing a carbodiimide chemical, such as EDC [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide] and DCC [N, N′-dicyclohexylcarbodiimide]. Antibodies amine groups can be numerous and highly reactive without additional chemical alterations. Because they can boost the efficiency of the EDC-mediated coupling, N-hydroxy succinimide (NHS) and N-hydroxy sulfosuccinimide (sulfo-NHS) are frequently utilized during the process [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. The possibility of the Ab being crosslinked between and inside molecules is decreased when NHS or sulfo-NHS is present because it produces a more stable intermediate, and carbodiimide chemistry has the potential to affect the biological effect and targeting potential of Abs by causing them to randomly immobilize on the nanoparticle surface since the majority of NH<sub>2</sub> groups present in the Fab region may be reactive. Another method of conjugation, known as maleimide chemistry, involves attaching to the -SH (sulfhydryl groups), present on the adjacent chains of the cysteine amino acids present in mAbs. Using an oxidative process, disulphide (-S-S-) bonds are exploited to couple pairs of cysteine sulfhydryl groups. IgG Abs often have disulphide connections on the hinge region of their structures. The mAb can split into monovalent halves when disulphide links are reduced, but the antigen-binding effectiveness of the 3D structure is unaffected. Since only free sulfhydryl groups are allowed to be utilized in maleimide chemistry, disulphide bonds must be reduced by sulfhydryl-addition or reducing reagents [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>]. The 2-iminothiolane and N-succinimidyl Sacetylthioacetate sulfhydryl addition agents can change the amine group of lysine residues into a thiol group, but the ability of an antibody to attach with its target may be hampered if the quantity of thiol groups increases because site specified selectivity may be reduced. The most accepted crosslinking agents utilized in maleimide chemistry Sulfo-SMCC are only SMCC along with their PEGylated equivalents [<a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>, <a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]. Additionally, click chemistry, which was also suggested for antibody-drug conjugates, is a set of straightforward chemical reactions that are both highly effective and stereospecific [<a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>]. It offers a great platform for biological applications because of its selectivity, orthogonal features to the majority of known reactions, and generation of very few by-products.</p></section><section id="Sec19"><h3 class="pmc_sec_title">Components of ACNPs</h3>
<p id="Par32">ACNPs structurally share homology with ADCs, which include a therapeutic payload, a nanoparticle carrier, a targeting ligand, often an antibody or its fragment, and an optional linker. The choice and inclusion of these components are crucial to determine the physicochemical stability, biodistribution, and therapeutic potency of ACNPs.</p>
<ol class="list" style="list-style-type:lower-alpha">
<li><p id="Par34"><strong>Nanoparticle core material</strong>: ACNPs use a wide variety of nanocarriers including liposomes, polymeric nanoparticles (e.g., PLGA, PEG-PLA), metallic nanoparticles (e.g., gold, silver, iron oxide), silica-based carriers, and dendrimers [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]. Each nanoparticle type has certain physicochemical and pharmacological properties. Polymeric nanoparticles are defined by their biodegradability and ability for effective encapsulation of hydrophobic drugs, whereas liposomes enable encapsulation of hydrophilic and lipophilic drugs based on their bilayer structure [<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>]. Metallic nanoparticles offer improved optical and magnetic properties, enabling dual functionalities in diagnostic and therapeutic purposes [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>].</p></li>
<li><p id="Par35"><strong>Therapeutic cargo</strong>: The ACNPs offer much more flexibility in payload design than do ADCs, which usually incorporate extremely potent small-molecule drugs such as auristatins and maytansinoids [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]. They can be made to carry traditional chemotherapeutic drugs (e.g., paclitaxel, doxorubicin), genetic material (e.g., siRNA, mRNA, CRISPR), proteins, enzymes, or imaging agents [<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]. Depending on the nanoparticle composition, environment, and availability of cleavable linkers, drug release may be controlled. This way, the drug’s site and time of action are strictly regulated.</p></li>
<li><p id="Par36"><strong>Linkers</strong>: Linkers in ACNPs play dual roles: facilitating antibody attachment to the nanoparticle and enabling drug release in response to physiological cues [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Covalent conjugation strategies include EDC/NHS-mediated amide bond formation, maleimide-thiol coupling, and bio-orthogonal click chemistry. For responsive release, pH-sensitive linkers such as hydrazones, redox-sensitive disulfide bonds, and enzyme-cleavable peptides (e.g., cathepsin B substrates) are frequently used [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>]. The choice of linker is dictated by the intended mechanism of release and the physicochemical compatibility with the nanoparticle system.</p></li>
<li><p id="Par37"><strong>Targeting moiety</strong>: The full-size monoclonal antibodies are largely favored for their specificity and established status in clinical practice. Shorter antibody fragments like Fab, single-chain variable fragments (scFv), diabodies, and nanobodies (VHH) are finding importance more and more. The smaller fragments have the distinct advantage of being capable of permeating tumors more effectively, yielding a lower intensity immune response, and having more control over their orientation [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]. They can be engineered to bind to peptide or protein-based nanoparticles, which allows them to target multiple targets at one time. Targeting moiety selection depends on numerous factors like the availability of antigen, the rate at which the receptors get internalized by cells, and the desired behavior of the drug.</p></li>
</ol></section><section id="Sec20"><h3 class="pmc_sec_title">Antibody orientation and surface conjugation chemistry</h3>
<p id="Par38">The correct orientation of antibodies on the nanoparticle surface is crucial if binding capacity of the antigen-recognition regions (Fab) is to be preserved [<a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]. The typical approach is to attach the antibodies via the Fc region, thereby making the Fab arms free to carry out recognition of the targets. There are a variety of non-covalent interactions such as those involving Protein A or Protein G; or covalent linkages that can be formed if cysteine sites or glycosylation sites are engineered onto the Fc domain [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>]. The covalent routes include maleimide-thiol chemistry for thiol groups introduced either onto the antibody or the nanoparticle surface, EDC/NHS coupling to create a stable amide bond between carboxyl and amine groups, or click chemistry (for example azide-alkyne cycloaddition) which confers a very high level of specificity and efficiency in mild conditions. The surface density of the antibody is also a factor that influences target efficiency and biodistribution. High densities cause extreme steric hindrance and aggregation, while low densities diminish the targeting [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>]. Optimization of the ratio of antibody-to-nanoparticles is always done either by empirical studies or by surface quantification assays like ELISA, BCA, or flow cytometry [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>]. An important consideration is to maintain a conjugation method that is consistent and reproducible such that the ACNPs are reproducible from batch to batch and consistent in function. With this modular design, ACNPs can be made suitable for anything from cancer therapy to gene delivery and diagnostic imaging.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Mechanism of action of ACNPs</h3>
<p id="Par39">The linker, utilized to conjugate the antibody to the polymers or lipids, does not affect how quickly the drug is released from ACNPs. Drug release occurs in these formulations due to drug diffusion and particle disintegration. Although it is practically difficult to restrict a little bit of leaching of the drug from NPs except when covalently bonded, using lower potency chemotherapies may make it possible to endure a tolerable premature release of the medication. Drug retention in polymeric NPs till uptake has been examined using the technique of ion pairing. This technique restricts early drug release by keeping the medicines within the nanoparticle for a more extended period through electrostatic interactions. It lengthens the therapeutic window once the drug reaches the disease site [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>].</p></section><section id="Sec22"><h3 class="pmc_sec_title">Characterization methods of ACNPs</h3>
<p id="Par40">Characterization of the synthesized NPs and characterization of MAbs conjugated NPs are the two categories into which methodologies for characterization of antibody conjugated NPs fall [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>, <a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]. Nanoparticle characterization methods include UV-visible spectroscopy, Zeta potential, SEM, XRD, FTIR, DSC, and NMR, as shown in Fig. <a href="#Fig4" class="usa-link">4</a>. Techniques like SDS-PAGE to separate, characterize, and identify proteins and protein mixtures, as well as to keep track of mAbs size fragmentation overall, SEC to determine equal proportions of high molecular mass and monomeric (intact mAb) species in samples of mAb and mAb-like drug substances and drug products, MS to validate conjugation and calculate the average DAR, NTA (Nanoparticle Tracking analysis) to check the size distribution of nanoparticles and antibody-modified nanoparticles, XPS (X-ray photoelectron spectroscopy) to confirm binding of the antibody to the NPs by assessing elemental composition and chemical and other techniques mentioned in Fig. <a href="#Fig5" class="usa-link">5</a> are utilized to characterize antibody-conjugated NPs.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361037_11671_2025_4303_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51a/12361037/78f59f12ede9/11671_2025_4303_Fig4_HTML.jpg" loading="lazy" id="d33e1364" height="398" width="708" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Characterization techniques to study the physicochemical properties of nanoparticles</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361037_11671_2025_4303_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51a/12361037/50cfdb8ba0e2/11671_2025_4303_Fig5_HTML.jpg" loading="lazy" id="d33e1441" height="622" width="708" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Characterization techniques for antibody-conjugated nanoparticles</p></figcaption></figure><p id="Par41"><strong>Electron microscopy (SEM/TEM)</strong>: SEM images surface morphology, showing antibody-induced roughness, whereas TEM identifies the core-shell structure. TEM in antibody-conjugated nanoparticles reveals conformational changes or layering resulting from antibody binding. Its primary strength lies in its unmatched resolution, which assists in identifying the structural integrity and conjugation. TEM, however, requires advanced sample preparation and can cause beam-related damage. SEM is effective in identifying surface modifications, such as coatings or functionalization. Its primary strength lies in the unambiguous visualization of the surface. It only gives surface information and usually requires sample coating with conductive materials, which may distort biological surfaces [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p>
<p id="Par42"><strong>Dynamic light scattering (DLS)</strong>: DLS quantifies hydrodynamic size variation on conjugation of antibodies, and it detects aggregation and verifies successful functionalization by an increase in particle diameter. The main advantages of DLS are its ease of use, speed, and applicability to aqueous systems. It is, however, aggregate and dust sensitive, and it fails in highly polydisperse systems. It is also unable to differentiate between loose clusters and monomers [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>, <a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p>
<p id="Par43"><strong>Zeta potential</strong> is utilized to determine the electrostatic potential at the nanoparticle surface and is functionally connected with colloidal stability. Conjugation with antibodies normally changes surface charge. The method is utilized in the prediction of aggregation propensity and tracking the reproducibility of conjugation batches. The measurement, however, is ionic strength and pH of the medium, which are sensitive and also affect the interpretation of complicated protein-rich biological buffers [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p>
<p id="Par44"><strong>X-ray diffraction (XRD)</strong> is used to investigate the crystalline or amorphous nature of nanoparticles. XRD is used to verify whether conjugation has any effect on the core crystallinity in the case of antibody-conjugated systems. XRD is helpful in determining structural phases and confirming synthesis protocols. XRD is less informative for amorphous materials or ultra-small nanoparticles and does not give any information about the bioconjugated surface directly [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p>
<p id="Par45"><strong>Fourier transform infrared spectroscopy (FTIR)</strong> is a good method for the identification of chemical functional groups and the assessment of conjugation by specific bond formation. In the case of antibody-nanoparticle conjugates, FTIR will identify characteristic amide bonds (I and II), indicating successful conjugation. FTIR is quick and involves little sample preparation. Peak overlap, particularly in complex conjugates can, however, prevent unequivocal assignment. FTIR is also more qualitative than quantitative, which restricts estimation of surface density of antibodies [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p>
<p id="Par46"><strong>Differential scanning calorimetry (DSC)</strong> detects heat flow by way of thermal transitions, which could reflect nanoparticle stability and antibody denaturation. DSC is most important in establishing the influence of storage conditions, processing, or formulation on conjugate stability. DSC can detect very slight transitions and generate thermodynamic information on the system. Its limitation is that it needs pure and homogeneous samples, and the information is typically related to other procedures for structural interpretation [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>].</p></section><section id="Sec23"><h3 class="pmc_sec_title"><strong>Patents and clinical trials of Antibody-Conjugated nanoparticles</strong></h3>
<p id="Par47">Recent patents exhibit advancements in ACNP design for therapy and diagnostics. Patent US10583156 includes nanoparticles with antigens and antibodies for immunotherapy to target B cell receptors to improve immune response. Patent US20210380676 includes anti-AMHRII antibody-conjugated nanoparticles to induce sterilization by targeting gonad cells and exhibits non-cancer application. WO2022001234 also includes PEGylated liposomes with conjugation of anti-CD20 antibodies for lymphoma treatment, enhancing drug stability and delivery.</p>
<p id="Par48">ACNP clinical trials are still limited to ADCs, with the majority in the initial stages. A Phase I trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02646319" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02646319</a>) assesses trastuzumab-conjugated gold nanoparticles for HER2-positive breast cancer with enhanced tumor targeting but minimal efficacy data due to small sample size. Another trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03585777" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03585777</a>) explores anti-EGFR antibody-conjugated nanoparticles for head and neck cancer with imaging and drug delivery emphasis, with initial results showing enhanced tumor specificity. No FDA approval has been given to any ACNPs yet, reflecting issues in scalability.</p></section><section id="Sec24"><h3 class="pmc_sec_title">Biomedical applications of ACNPs</h3>
<p id="Par49">Antibody-conjugated nanoparticles (ACNPs) have demonstrated significant promise in biomedical applications, particularly in targeted cancer therapy, imaging, neurodegenerative disease treatment, and antimicrobial strategies. In cancer models, ACNPs enhance drug accumulation at tumor sites while reducing systemic toxicity. For instance, trastuzumab-conjugated PLGA nanoparticles loaded with paclitaxel exhibited superior tumor growth inhibition (~ 75% reduction over 21 days) in HER2-positive breast cancer xenograft mice, compared to free drug (~ 40%) with minimal adverse effects [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>]. In vivo imaging also benefits from ACNPs; anti-EGFR antibody-conjugated gold nanoparticles markedly improved CT contrast in colorectal tumor-bearing mice, achieving a 3.5-fold increase in signal intensity at the tumor site within 24 h post-injection [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]. Beyond oncology, ACNPs facilitate targeted delivery across the blood-brain barrier (BBB). Lipid nanoparticles conjugated with anti-transferrin receptor antibodies effectively delivered siRNA in a Huntington’s disease mouse model, resulting in ~ 50% gene knockdown in the brain and observable functional recovery [<a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>]. Furthermore, ACNPs enhance the precision of photothermal and photodynamic therapies. In HER2-positive tumors, anti-HER2 gold nanorods enabled focused ablation under near-infrared light, leading to over 90% tumor shrinkage within five days with minimal off-target damage. In infectious disease models, antibody-conjugated silver nanoparticles targeting Pseudomonas aeruginosa biofilms significantly reduced bacterial loads in a mouse lung infection model, achieving a 2-log reduction in CFUs and improving survival rates to 80% [<a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>]. These in vivo results underscore the versatility and translational potential of ACNPs in precision medicine.</p></section></section><section id="Sec25"><h2 class="pmc_sec_title">In-vitro assays utilized in ADCs and ACNPs</h2>
<p id="Par51">A matrix of different mAbs, linkers, and cytotoxic payloads are routinely and systematically evaluated in-vitro as part of current methodologies for preclinical lead selection. The competition binding assay, which can be used to test if the conjugation procedure or the presence of the drug hindered the antigen binding and to evaluate an ADC’s capacity to outbid alternative ligands for binding to the target antigens is one of the in-vitro assays that have been compiled here for the in-vitro characterization of ADCs. The ADCs and ACNP’s in vitro cytotoxic properties can be assessed by cell viability assays such as the MTT assay, which is a colorimetric test that determines how many viable cells are present in a sample of living cells by cleaving its tetrazolium ring in active mitochondria of living cells on a particular cell line related to target disease such as A549 cell line for lung tumour, SK-BR-3 for breast cancer, NCI-H460 for lung cancer, etc [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>]. These studies may be carried out in 2D or 3D cell culture systems, and they might also include extracellular matrix elements, stromal cells, or immune cells to better mimic the tumor microenvironment.</p>
<p id="Par52">Other assays like evaluation of antioxidant activity by ABTS or DPPH assay, morphological characteristics of the nucleus by DAPI stain, cell cycle analysis, apoptosis studies, affinity assays, and various other studies can be performed based upon the application related to selected mAbs, therapeutic agents, and NPs as illustrated in Table <a href="#Tab3" class="usa-link">3</a> [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>].</p>
<section class="tw xbox font-sm" id="Tab3"><h3 class="obj_head">Table 3.</h3>
<div class="caption p"><p>In-vitro assays used to establish ADCs and acnps</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Assay type</th>
<th align="left" colspan="1" rowspan="1">Methods</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Internalization assays</td>
<td align="left" colspan="1" rowspan="1">Flow cytometry-based internalization, Confocal microscopy-based internalization, Ligand-binding assay-based internalization, Radioactive-based internalization, High-content imaging-based internalization.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cell viability assays</td>
<td align="left" colspan="1" rowspan="1">MTT, XTT, WST-1, LDH, Annexin V, Alamar blue, Trypan blue exclusion, Crystal violet, ATP, Cell titre-Glo, Neutral red uptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Binding assays</td>
<td align="left" colspan="1" rowspan="1">ELISA, FRET, SPR, Biacore, ITC, Flow cytometry-based binding, Radioimmunoassay, Western blotting, Immunohistochemistry, Immunofluorescence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stability assays</td>
<td align="left" colspan="1" rowspan="1">Chemical stability (pH, temperature, and light exposure), Physicochemical stability, Aggregation assay, Immunogenicity assay, Stability in Biological fluids, shelf life</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p70"><p>MTT- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; XTT- methoxynitrosulfophenyl-tetrazolium carboxanilide; WST-1- water-soluble tetrazolium salt; LDH- lactate dehydrogenase; ATP- adenosine triphosphate; ELISA- enzyme-linked immunosorbent assay; FRET- fluorescence resonance energy transfer; SPR- surface plasmon resonance; ITC- isothermal Titration calorimetry</p></div></div></section></section><section id="Sec26"><h2 class="pmc_sec_title">Comparison of ADCs and ACNPs</h2>
<p id="Par54">ADCs and ACNPs have emerged as two of the most promising targeted drug delivery methods for the treatment of cancer over the last two decades. While ADCs use cytotoxic drugs chemically linked to mAb via linker molecules, ACNPs represent encapsulated therapeutic agents conjugated to mAb, where drug release depends on pH-sensitive or enzyme-responsive systems. One of the most prominent limitations of the ADCs is the drug release even before reaching the target site, leading to systemic toxicity. In contrast, ACNPs provide controlled release of the drug and reduced off-site targets and systemic side effects.</p>
<p id="Par55">Some of the ADCs, such as brentuximab vedotin and trastuzumab emtansine, are approved by the FDA and commonly used for cancer therapy. ACNPs have demonstrated excellent performance in tests but are not yet approved since they are still under clinical trials. The advantages of ADCs include known accuracy and experience with the regulatory agency, while ACNPs possess higher capacity for carrying drugs, stability, and flexibility in surface modification. ADCs have the disadvantages of limited tumor-penetrating capability and long-term resistance, while ACNPs possess disadvantages in complex production, potential toxic effects from nanoparticles, and regulation (Table <a href="#Tab4" class="usa-link">4</a>).</p>
<section class="tw xbox font-sm" id="Tab4"><h3 class="obj_head">Table 4.</h3>
<div class="caption p"><p>Key features of ADCs and ADNPs for drug delivery</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Feature</th>
<th align="left" colspan="1" rowspan="1">ADCs</th>
<th align="left" colspan="1" rowspan="1">ACNPs</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Payload type</td>
<td align="left" colspan="1" rowspan="1">Cytotoxic drugs</td>
<td align="left" colspan="1" rowspan="1">Nanoparticles with drugs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Drug release mechanism</td>
<td align="left" colspan="1" rowspan="1">Linker-dependent</td>
<td align="left" colspan="1" rowspan="1">Tunable (pH/enzyme-responsive)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Toxicity profile</td>
<td align="left" colspan="1" rowspan="1">Higher systemic toxicity</td>
<td align="left" colspan="1" rowspan="1">Reduced toxicity (controlled release)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Clinical approval status</td>
<td align="left" colspan="1" rowspan="1">Multiple FDA-approved (Detailed in Table <a href="#Tab1" class="usa-link">1</a>)</td>
<td align="left" colspan="1" rowspan="1">None yet (under trials)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Merits</td>
<td align="left" colspan="1" rowspan="1">High specificity, FDA approvals, reduced systemic toxicity</td>
<td align="left" colspan="1" rowspan="1">High drug stability, tunable release, high loading capacity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Demerits</td>
<td align="left" colspan="1" rowspan="1">Limited tumor penetration, resistance, off-target effects</td>
<td align="left" colspan="1" rowspan="1">No FDA approvals, potential NP toxicity, complex manufacturing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Applications</td>
<td align="left" colspan="1" rowspan="1">Cancer therapy (e.g., lymphoma, breast cancer)</td>
<td align="left" colspan="1" rowspan="1">Cancer therapy, diagnostics, gene delivery</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec27"><h2 class="pmc_sec_title">Challenges and future directions</h2>
<p id="Par57">The design of therapeutic mAbs has generally improved, and the synthesis of conjugates has specifically enhanced, resulting in better homogeneity, both of which have benefitted the creation of ADCs. As connecting techniques and warheads have become more varied, new options have arisen to enhance medication delivery to cancer cells while lowering the payload’s exposure to healthy cells. The most difficult hurdles for the therapeutic applications of ADCs are the lethal effects, making it crucial to understand the factors that influence ADC toxicity, whether used alone or in conjunction with other treatments. Improvements must be made to the cytotoxic payload’s potency to decrease the MED (minimum effective dose) or to the tumor specificity to raise the maximum tolerated dose to increase the pharmaceutical index of ADCs. The antibody’s specificity presents another difficulty. According to the reasoning, target antigens must express heavily in tumors while barely expressing in healthy tissues to be considered tumor-specific. However, most antigens expressed in cancerous cells are also expressed in normal tissues, making them tumor-associated instead of tumor-specific. ADCs are hybrid compounds; thus, it is necessary to consider both the mAb (biological compound) and the drug and drug-linker combination product quality attributes. Because of this, early-developability evaluation calls for cutting-edge structural and analytical techniques, such as CE coupled to MS, ion mobility mass spectrometry, and two-dimensional liquid chromatography. These new techniques enable a thorough understanding of significant structural elements connected to the ADC function. Furthermore, the emergence of recent ADCs has rekindled the importance of natural cytotoxic compounds, which are frequently powerful cytotoxic drugs but often have intolerable toxicities. Finally, the action of ADCs in actual patients cannot be predicted using current preclinical models. Even though many ADCs exhibit therapeutic advantages in rat tumor models, many are ineffective in human clinical settings. The distinction between human and rodent antigens is one of the causes. It is crucial to thoroughly define the human antigen and choose the matched antibody to overcome this hurdle. When it comes to ACNPs, a notable concern is the possible short-term and long-term harmful consequences that a non-biodegradable NP may have. The intricacy is further raised by the unique physical and chemical characteristics of each mAb-targeted NPs and each nanoparticle design, which must be critically evaluated before being employed in therapeutic applications. Furthermore, the possible impacts of drug pharmacokinetic parameters, including half-life, clearance, and characteristics on the nanoparticle’s size, shape, and surface, are essential. Small molecules (nm) are thought to enter the bloodstream, extravasate into tissues, and interact with their target cells by internalizing them. However, most studies have also found that toxic NPs are often smaller. To develop the best formulations of ACNPs, extensive testing of NPs and nanoparticle-conjugated mAbs in both in-vitro and in-vivo systems is required to elucidate how NPs might interact with body cells and tissues.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Authors thanks Symbiosis International (Deemed University) for facility and support.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>T.D conceptualized, collected literature, analyzed, interpreted and wrote the manuscript. A.A, H.N and A.V collected literature and reviewed the manuscript. S.R reviewed and rewrote the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Open access funding provided by Symbiosis International (Deemed University). The authors received no external financial support for the research, authorship or publication of this article.</p></section><section id="notes3"><h2 class="pmc_sec_title">Availability of data and materials</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar2"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par58">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par59">Not applicable.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par60">The authors declare no competing interests.</p></section><section id="FPar5"><h3 class="pmc_sec_title">Clinical trial number</h3>
<p id="Par61">Not applicable.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Ghagane SC, Puranik SI, Gan SH, Hiremath MB, Nerli RB, Ravishankar MV. Frontiers of monoclonal antibodies: applications in medical practices. Hum Antib. 2018;26(3):135–42. 10.3233/HAB-170331.</cite> [<a href="https://doi.org/10.3233/HAB-170331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29060935/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghagane%20SC,%20Puranik%20SI,%20Gan%20SH,%20Hiremath%20MB,%20Nerli%20RB,%20Ravishankar%20MV.%20Frontiers%20of%20monoclonal%20antibodies:%20applications%20in%20medical%20practices.%20Hum%20Antib.%202018;26(3):135%E2%80%9342.%2010.3233/HAB-170331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Cai HH, Chen X. Monoclonal antibodies for cancer therapy approved by FDA. MOJ Immunol. 2016;4(2):2–4. 10.15406/moji.2016.03.00120.</cite> [<a href="https://scholar.google.com/scholar_lookup?Cai%20HH,%20Chen%20X.%20Monoclonal%20antibodies%20for%20cancer%20therapy%20approved%20by%20FDA.%20MOJ%20Immunol.%202016;4(2):2%E2%80%934.%2010.15406/moji.2016.03.00120." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Singh S, Tank NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal antibodies: a review. Curr Clin Pharmacol. 2018;13(2):85–99. 10.2174/1574884712666170809124728.
</cite> [<a href="https://doi.org/10.2174/1574884712666170809124728" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28799485/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Singh%20S,%20Tank%20NK,%20Dwiwedi%20P,%20Charan%20J,%20Kaur%20R,%20Sidhu%20P,%20Chugh%20VK.%20Monoclonal%20antibodies:%20a%20review.%20Curr%20Clin%20Pharmacol.%202018;13(2):85%E2%80%9399.%2010.2174/1574884712666170809124728." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1–30. 10.1186/s12929-019-0592-z.
</cite> [<a href="https://doi.org/10.1186/s12929-019-0592-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6939334/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31894001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20RM,%20Hwang%20YC,%20Liu%20IJ,%20Lee%20CC,%20Tsai%20HZ,%20Li%20HJ,%20Wu%20HC.%20Development%20of%20therapeutic%20antibodies%20for%20the%20treatment%20of%20diseases.%20J%20Biomed%20Sci.%202020;27(1):1%E2%80%9330.%2010.1186/s12929-019-0592-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance—challenges and solutions. Drug Resist Updates. 2015;18(1):36–46. 10.1016/j.drup.2014.11.001.</cite> [<a href="https://doi.org/10.1016/j.drup.2014.11.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25476546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shefet-Carasso%20L,%20Benhar%20I.%20Antibody-targeted%20drugs%20and%20drug%20resistance%E2%80%94challenges%20and%20solutions.%20Drug%20Resist%20Updates.%202015;18(1):36%E2%80%9346.%2010.1016/j.drup.2014.11.001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Therapy. 2022;7(1):93. 10.1038/s41392-022-00947-7.</cite> [<a href="https://doi.org/10.1038/s41392-022-00947-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8941077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35318309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fu%20Z,%20Li%20S,%20Han%20S,%20Shi%20C,%20Zhang%20Y.%20Antibody%20drug%20conjugate:%20the%20biological%20missile%20for%20targeted%20cancer%20therapy.%20Signal%20Transduct%20Target%20Therapy.%202022;7(1):93.%2010.1038/s41392-022-00947-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. 10.1038/nrd.2016.268.
</cite> [<a href="https://doi.org/10.1038/nrd.2016.268" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28303026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beck%20A,%20Goetsch%20L,%20Dumontet%20C,%20Corva%C3%AFa%20N.%20Strategies%20and%20challenges%20for%20the%20next%20generation%20of%20antibody%E2%80%93drug%20conjugates.%20Nat%20Rev%20Drug%20Discov.%202017;16(5):315%E2%80%9337.%2010.1038/nrd.2016.268." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17(1):339–51. 10.1208/s12248-014-9710-8.
</cite> [<a href="https://doi.org/10.1208/s12248-014-9710-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4365093/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25604608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McCombs%20JR,%20Owen%20SC.%20Antibody%20drug%20conjugates:%20design%20and%20selection%20of%20linker,%20payload%20and%20conjugation%20chemistry.%20AAPS%20J.%202015;17(1):339%E2%80%9351.%2010.1208/s12248-014-9710-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. 2005;13(17):5043–54. 10.1016/j.bmc.2005.04.084.
</cite> [<a href="https://doi.org/10.1016/j.bmc.2005.04.084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15955702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jaracz%20S,%20Chen%20J,%20Kuznetsova%20LV,%20Ojima%20I.%20Recent%20advances%20in%20tumor-targeting%20anticancer%20drug%20conjugates.%20Bioorg%20Med%20Chem.%202005;13(17):5043%E2%80%9354.%2010.1016/j.bmc.2005.04.084." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody–drug conjugates: the last decade. Pharmaceuticals. 2020;13(9):245. 10.3390/ph13090245.
</cite> [<a href="https://doi.org/10.3390/ph13090245" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7558467/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32937862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Joubert%20N,%20Beck%20A,%20Dumontet%20C,%20Denevault-Sabourin%20C.%20Antibody%E2%80%93drug%20conjugates:%20the%20last%20decade.%20Pharmaceuticals.%202020;13(9):245.%2010.3390/ph13090245." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody–drug conjugates. Nat Chem. 2016;8(2):114–9. 10.1038/nchem.2415.
</cite> [<a href="https://doi.org/10.1038/nchem.2415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26791893/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chudasama%20V,%20Maruani%20A,%20Caddick%20S.%20Recent%20advances%20in%20the%20construction%20of%20antibody%E2%80%93drug%20conjugates.%20Nat%20Chem.%202016;8(2):114%E2%80%939.%2010.1038/nchem.2415." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Johnston MC, Scott CJ. Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. Drug Discov Today: Technol. 2018;30(1):63–9. 10.1016/j.ddtec.2018.10.003.</cite> [<a href="https://doi.org/10.1016/j.ddtec.2018.10.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30553522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johnston%20MC,%20Scott%20CJ.%20Antibody%20conjugated%20nanoparticles%20as%20a%20novel%20form%20of%20antibody%20drug%20conjugate%20chemotherapy.%20Drug%20Discov%20Today:%20Technol.%202018;30(1):63%E2%80%939.%2010.1016/j.ddtec.2018.10.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Arruebo M, Valladares M, González-Fernández Á. Antibody-conjugated nanoparticles for biomedical applications. J Nanomater. 2009;1(1):439389. 10.1155/2009/439389.</cite> [<a href="https://scholar.google.com/scholar_lookup?Arruebo%20M,%20Valladares%20M,%20Gonz%C3%A1lez-Fern%C3%A1ndez%20%C3%81.%20Antibody-conjugated%20nanoparticles%20for%20biomedical%20applications.%20J%20Nanomater.%202009;1(1):439389.%2010.1155/2009/439389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Sivaram AJ, Wardiana A, Howard CB, Mahler SM, Thurecht KJ. Recent advances in the generation of antibody–nanomaterial conjugates. Adv Healthc Mater. 2018;7(1):1700607. 10.1002/adhm.201700607.</cite> [<a href="https://doi.org/10.1002/adhm.201700607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28961378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sivaram%20AJ,%20Wardiana%20A,%20Howard%20CB,%20Mahler%20SM,%20Thurecht%20KJ.%20Recent%20advances%20in%20the%20generation%20of%20antibody%E2%80%93nanomaterial%20conjugates.%20Adv%20Healthc%20Mater.%202018;7(1):1700607.%2010.1002/adhm.201700607." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biol Targets Ther. 2019;1(1):33–51. 10.2147/BTT.S166310.</cite> [<a href="https://doi.org/10.2147/BTT.S166310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6503308/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31118560/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cruz%20E,%20Kayser%20V.%20Monoclonal%20antibody%20therapy%20of%20solid%20tumors:%20clinical%20limitations%20and%20novel%20strategies%20to%20enhance%20treatment%20efficacy.%20Biol%20Targets%20Ther.%202019;1(1):33%E2%80%9351.%2010.2147/BTT.S166310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12(1):14. 10.1158/1424-9634.DCL-14.12.1.
</cite> [<a href="/articles/PMC3380347/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22896759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Scott%20AM,%20Allison%20JP,%20Wolchok%20JD.%20Monoclonal%20antibodies%20in%20cancer%20therapy.%20Cancer%20Immun.%202012;12(1):14.%2010.1158/1424-9634.DCL-14.12.1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Schwaber J, Cohen EP. Human× mouse somatic cell hybrid clone secreting Immunoglobulins of both parental types. Nature. 1973;244(5416):444–7. 10.1038/244444a0.
</cite> [<a href="https://doi.org/10.1038/244444a0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4200460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schwaber%20J,%20Cohen%20EP.%20Human%C3%97%20mouse%20somatic%20cell%20hybrid%20clone%20secreting%20Immunoglobulins%20of%20both%20parental%20types.%20Nature.%201973;244(5416):444%E2%80%937.%2010.1038/244444a0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J. 2015;63(6):650. 10.7727/wimj.2013.241.</cite> [<a href="https://doi.org/10.7727/wimj.2013.241" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4663950/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25803383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Coulson%20A,%20Levy%20A,%20Gossell-Williams%20M.%20Monoclonal%20antibodies%20in%20cancer%20therapy:%20mechanisms,%20successes%20and%20limitations.%20West%20Indian%20Med%20J.%202015;63(6):650.%2010.7727/wimj.2013.241." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Alejandra WP, Irene JP, Antonio GS, Patricia RG, Elizabeth TA, Aleman-Aguilar JP, Rebeca GV. Production of monoclonal antibodies for therapeutic purposes: a review. Int Immunopharmacol. 2023;120(1):110376. 10.1016/j.intimp.2023.110376.
</cite> [<a href="https://doi.org/10.1016/j.intimp.2023.110376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37244118/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alejandra%20WP,%20Irene%20JP,%20Antonio%20GS,%20Patricia%20RG,%20Elizabeth%20TA,%20Aleman-Aguilar%20JP,%20Rebeca%20GV.%20Production%20of%20monoclonal%20antibodies%20for%20therapeutic%20purposes:%20a%20review.%20Int%20Immunopharmacol.%202023;120(1):110376.%2010.1016/j.intimp.2023.110376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Holzlöhner P, Hanack K. Generation of murine monoclonal antibodies by Hybridoma technology. J Vis Exp. 2017;1(119):54832. 10.3791/54832.</cite> [<a href="https://doi.org/10.3791/54832" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5407676/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28117810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Holzl%C3%B6hner%20P,%20Hanack%20K.%20Generation%20of%20murine%20monoclonal%20antibodies%20by%20Hybridoma%20technology.%20J%20Vis%20Exp.%202017;1(119):54832.%2010.3791/54832." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64(1):15–29. 10.1146/annurev-med-050311-201823.
</cite> [<a href="https://doi.org/10.1146/annurev-med-050311-201823" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23043493/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sievers%20EL,%20Senter%20PD.%20Antibody-drug%20conjugates%20in%20cancer%20therapy.%20Annu%20Rev%20Med.%202013;64(1):15%E2%80%9329.%2010.1146/annurev-med-050311-201823." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32(1):3494–507. 10.1007/s11095-015-1624-3.
</cite> [<a href="https://doi.org/10.1007/s11095-015-1624-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25585957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Damelin%20M,%20Zhong%20W,%20Myers%20J,%20Sapra%20P.%20Evolving%20strategies%20for%20target%20selection%20for%20antibody-drug%20conjugates.%20Pharm%20Res.%202015;32(1):3494%E2%80%93507.%2010.1007/s11095-015-1624-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Tong JT, Harris PW, Brimble MA, Kavianinia I. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. 2021;26(19):5847. 10.3390/molecules26195847.
</cite> [<a href="https://doi.org/10.3390/molecules26195847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8510272/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34641391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tong%20JT,%20Harris%20PW,%20Brimble%20MA,%20Kavianinia%20I.%20An%20insight%20into%20FDA%20approved%20antibody-drug%20conjugates%20for%20cancer%20therapy.%20Molecules.%202021;26(19):5847.%2010.3390/molecules26195847." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs. 2005;65(1):2405–27. 10.2165/00003495-200565160-00014.
</cite> [<a href="https://doi.org/10.2165/00003495-200565160-00014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16266206/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fenton%20C,%20Perry%20CM.%20Gemtuzumab%20ozogamicin:%20a%20review%20of%20its%20use%20in%20acute%20myeloid%20leukaemia.%20Drugs.%202005;65(1):2405%E2%80%9327.%2010.2165/00003495-200565160-00014." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428–36. 10.1158/1078-0432.CCR-11-0488.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-11-0488" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22003070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Katz%20J,%20Janik%20JE,%20Younes%20A.%20Brentuximab%20Vedotin%20(SGN-35).%20Clin%20Cancer%20Res.%202011;17(20):6428%E2%80%9336.%2010.1158/1078-0432.CCR-11-0488." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Ann Pharmacother. 2014;48(11):1484–93. 10.1177/1060028014545354.
</cite> [<a href="https://doi.org/10.1177/1060028014545354" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25082874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Corrigan%20PA,%20Cicci%20TA,%20Auten%20JJ,%20Lowe%20DK.%20Ado-trastuzumab%20emtansine:%20a%20HER2-positive%20targeted%20antibody-drug%20conjugate.%20Ann%20Pharmacother.%202014;48(11):1484%E2%80%9393.%2010.1177/1060028014545354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Tvito A, Rowe JM. Inotuzumab Ozogamicin for the treatment of acute lymphoblastic leukemia. Expert Opin Biol Ther. 2017;17(12):1557–64. 10.1080/14712598.2017.1387244.
</cite> [<a href="https://doi.org/10.1080/14712598.2017.1387244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29092647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tvito%20A,%20Rowe%20JM.%20Inotuzumab%20Ozogamicin%20for%20the%20treatment%20of%20acute%20lymphoblastic%20leukemia.%20Expert%20Opin%20Biol%20Ther.%202017;17(12):1557%E2%80%9364.%2010.1080/14712598.2017.1387244." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78(16):1763–7. 10.1007/s40265-018-1000-9.
</cite> [<a href="https://doi.org/10.1007/s40265-018-1000-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6323103/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30357593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dhillon%20S.%20Moxetumomab%20pasudotox:%20first%20global%20approval.%20Drugs.%202018;78(16):1763%E2%80%937.%2010.1007/s40265-018-1000-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Yip V, Lee MV, Saad OM, Ma S, Khojasteh SC, Shen BQ. Preclinical characterization of the distribution, catabolism, and elimination of a polatuzumab vedotin-piiq (POLIVY®) antibody–drug conjugate in Sprague Dawley rats. J Clin Med. 2021;10(6):1323. 10.3390/jcm10061323.
</cite> [<a href="https://doi.org/10.3390/jcm10061323" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8004598/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33806916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yip%20V,%20Lee%20MV,%20Saad%20OM,%20Ma%20S,%20Khojasteh%20SC,%20Shen%20BQ.%20Preclinical%20characterization%20of%20the%20distribution,%20catabolism,%20and%20elimination%20of%20a%20polatuzumab%20vedotin-piiq%20(POLIVY%C2%AE)%20antibody%E2%80%93drug%20conjugate%20in%20Sprague%20Dawley%20rats.%20J%20Clin%20Med.%202021;10(6):1323.%2010.3390/jcm10061323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS. Enfortumab vedotin in urothelial cancer. Ther Adv Urol. 2020;12(1):1756287220980192. 10.1177/17562872209801.
</cite> [<a href="https://doi.org/10.1177/1756287220980192" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7780177/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33447264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alt%20M,%20Stecca%20C,%20Tobin%20S,%20Jiang%20DM,%20Sridhar%20SS.%20Enfortumab%20vedotin%20in%20urothelial%20cancer.%20Ther%20Adv%20Urol.%202020;12(1):1756287220980192.%2010.1177/17562872209801." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501–8. 10.1007/s40265-020-01281-4.
</cite> [<a href="https://doi.org/10.1007/s40265-020-01281-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32144719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Keam%20SJ.%20Trastuzumab%20deruxtecan:%20first%20approval.%20Drugs.%202020;80(5):501%E2%80%938.%2010.1007/s40265-020-01281-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Hedgecorth J. Sacituzumab Govitecan-Hziy (Trodelvy™). Oncol Times. 2021;43(8):5–10. 10.1097/01.COT.0000749876.89266.8f.</cite> [<a href="https://scholar.google.com/scholar_lookup?Hedgecorth%20J.%20Sacituzumab%20Govitecan-Hziy%20(Trodelvy%E2%84%A2).%20Oncol%20Times.%202021;43(8):5%E2%80%9310.%2010.1097/01.COT.0000749876.89266.8f." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Matula Z, Uher F, Vályi-Nagy I, Mikala G. The effect of belantamab mafodotin on primary myeloma–stroma co-cultures: asymmetrical mitochondrial transfer between myeloma cells and autologous bone marrow stromal cells. Int J Mol Sci. 2023;24(6):5303. 10.3390/ijms24065303.
</cite> [<a href="https://doi.org/10.3390/ijms24065303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10048929/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36982377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Matula%20Z,%20Uher%20F,%20V%C3%A1lyi-Nagy%20I,%20Mikala%20G.%20The%20effect%20of%20belantamab%20mafodotin%20on%20primary%20myeloma%E2%80%93stroma%20co-cultures:%20asymmetrical%20mitochondrial%20transfer%20between%20myeloma%20cells%20and%20autologous%20bone%20marrow%20stromal%20cells.%20Int%20J%20Mol%20Sci.%202023;24(6):5303.%2010.3390/ijms24065303." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Lee A. Loncastuximab tesirine: first approval. Drugs. 2021;81(10):1229–33. 10.1007/s40265-021-01550-w.
</cite> [<a href="https://doi.org/10.1007/s40265-021-01550-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34143407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20A.%20Loncastuximab%20tesirine:%20first%20approval.%20Drugs.%202021;81(10):1229%E2%80%9333.%2010.1007/s40265-021-01550-w." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Perkey C. Tisotumab Vedotin (Tivdak™). Oncol Times. 2022;44(24):26–37. 10.1097/01.COT.0000911072.05892.ae.</cite> [<a href="https://scholar.google.com/scholar_lookup?Perkey%20C.%20Tisotumab%20Vedotin%20(Tivdak%E2%84%A2).%20Oncol%20Times.%202022;44(24):26%E2%80%9337.%2010.1097/01.COT.0000911072.05892.ae." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Spreen L. Mirvetuximab soravtansine-gynx (Elahere™). Oncol Times. 2023;45(8):6. 10.1097/01.COT.0000931988.98268.c3.</cite> [<a href="https://scholar.google.com/scholar_lookup?Spreen%20L.%20Mirvetuximab%20soravtansine-gynx%20(Elahere%E2%84%A2).%20Oncol%20Times.%202023;45(8):6.%2010.1097/01.COT.0000931988.98268.c3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Tashima T. Delivery of drugs into cancer cells using antibody–drug conjugates based on receptor-mediated endocytosis and the enhanced permeability and retention effect. Antibodies. 2022;11(4):78. 10.3390/antib11040078.
</cite> [<a href="https://doi.org/10.3390/antib11040078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9774242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36546903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tashima%20T.%20Delivery%20of%20drugs%20into%20cancer%20cells%20using%20antibody%E2%80%93drug%20conjugates%20based%20on%20receptor-mediated%20endocytosis%20and%20the%20enhanced%20permeability%20and%20retention%20effect.%20Antibodies.%202022;11(4):78.%2010.3390/antib11040078." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. 10.1056/NEJMoa1814017.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1814017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30516102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Von%20Minckwitz%20G,%20Huang%20CS,%20Mano%20MS,%20Loibl%20S,%20Mamounas%20EP,%20Untch%20M,%20Wolmark%20N,%20Rastogi%20P,%20Schneeweiss%20A,%20Redondo%20A,%20Fischer%20HH.%20Trastuzumab%20emtansine%20for%20residual%20invasive%20HER2-positive%20breast%20cancer.%20N%20Engl%20J%20Med.%202019;380(7):617%E2%80%9328.%2010.1056/NEJMoa1814017." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. 10.1056/NEJMoa1914510.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1914510" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7458671/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31825192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Modi%20S,%20Saura%20C,%20Yamashita%20T,%20Park%20YH,%20Kim%20SB,%20Tamura%20K,%20Andre%20F,%20Iwata%20H,%20Ito%20Y,%20Tsurutani%20J,%20Sohn%20J.%20Trastuzumab%20deruxtecan%20in%20previously%20treated%20HER2-positive%20breast%20cancer.%20N%20Engl%20J%20Med.%202020;382(7):610%E2%80%9321.%2010.1056/NEJMoa1914510." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets Therapy. 2019;12(1):1781–90. 10.2147/OTT.S162447.
</cite> [<a href="https://doi.org/10.2147/OTT.S162447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6402435/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30881031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zaman%20S,%20Jadid%20H,%20Denson%20AC,%20Gray%20JE.%20Targeting%20Trop-2%20in%20solid%20tumors:%20future%20prospects.%20OncoTargets%20Therapy.%202019;12(1):1781%E2%80%9390.%2010.2147/OTT.S162447." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>De Cecco M, Galbraith DN, McDermott LL. What makes a good antibody–drug conjugate? Expert Opin Biol Ther. 2021;21(7):841–7. 10.1080/14712598.2021.1880562.
</cite> [<a href="https://doi.org/10.1080/14712598.2021.1880562" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33605810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Cecco%20M,%20Galbraith%20DN,%20McDermott%20LL.%20What%20makes%20a%20good%20antibody%E2%80%93drug%20conjugate?%20Expert%20Opin%20Biol%20Ther.%202021;21(7):841%E2%80%937.%2010.1080/14712598.2021.1880562." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometr Syst Pharmacol. 2017;6(9):576–88. 10.1002/psp4.12224.
</cite> [<a href="https://doi.org/10.1002/psp4.12224" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5613179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28653357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ryman%20JT,%20Meibohm%20B.%20Pharmacokinetics%20of%20monoclonal%20antibodies.%20CPT%20Pharmacometr%20Syst%20Pharmacol.%202017;6(9):576%E2%80%9388.%2010.1002/psp4.12224." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Kunert R, Reinhart D. Advances in Recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(1):3451–61. 10.1007/s00253-016-7388-9.
</cite> [<a href="https://doi.org/10.1007/s00253-016-7388-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4803805/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26936774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kunert%20R,%20Reinhart%20D.%20Advances%20in%20Recombinant%20antibody%20manufacturing.%20Appl%20Microbiol%20Biotechnol.%202016;100(1):3451%E2%80%9361.%2010.1007/s00253-016-7388-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Spiess C, Bevers J, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, Scheer JM. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem. 2013;288(37):26583–93. 10.1074/jbc.M113.480483.
</cite> [<a href="https://doi.org/10.1074/jbc.M113.480483" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3772205/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23880771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Spiess%20C,%20Bevers%20J,%20Jackman%20J,%20Chiang%20N,%20Nakamura%20G,%20Dillon%20M,%20Liu%20H,%20Molina%20P,%20Elliott%20JM,%20Shatz%20W,%20Scheer%20JM.%20Development%20of%20a%20human%20IgG4%20bispecific%20antibody%20for%20dual%20targeting%20of%20interleukin-4%20(IL-4)%20and%20interleukin-13%20(IL-13)%20cytokines.%20J%20Biol%20Chem.%202013;288(37):26583%E2%80%9393.%2010.1074/jbc.M113.480483." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, De Haas M, Jonsdottir I. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2(1):599. 10.1038/ncomms1608.
</cite> [<a href="https://doi.org/10.1038/ncomms1608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3247843/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22186895/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stapleton%20NM,%20Andersen%20JT,%20Stemerding%20AM,%20Bjarnarson%20SP,%20Verheul%20RC,%20Gerritsen%20J,%20Zhao%20Y,%20Kleijer%20M,%20Sandlie%20I,%20De%20Haas%20M,%20Jonsdottir%20I.%20Competition%20for%20FcRn-mediated%20transport%20gives%20rise%20to%20short%20half-life%20of%20human%20IgG3%20and%20offers%20therapeutic%20potential.%20Nat%20Commun.%202011;2(1):599.%2010.1038/ncomms1608." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. 2022;14(2):396. 10.3390/pharmaceutics14020396.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics14020396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8874516/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35214128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sheyi%20R,%20de%20la%20Torre%20BG,%20Albericio%20F.%20Linkers:%20an%20assurance%20for%20controlled%20delivery%20of%20antibody-drug%20conjugate.%20Pharmaceutics.%202022;14(2):396.%2010.3390/pharmaceutics14020396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Tedeschini T, Campara B, Grigoletto A, Zanotto I, Cannella L, Gabbia D, Matsuno Y, Suzuki A, Yoshioka H, Armirotti A, De Martin S. Optimization of a pendant-shaped pegylated linker for antibody-drug conjugates. J Controll Release. 2024;375:74–89. 10.1016/j.jconrel.2024.08.049.</cite> [<a href="https://doi.org/10.1016/j.jconrel.2024.08.049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39216599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tedeschini%20T,%20Campara%20B,%20Grigoletto%20A,%20Zanotto%20I,%20Cannella%20L,%20Gabbia%20D,%20Matsuno%20Y,%20Suzuki%20A,%20Yoshioka%20H,%20Armirotti%20A,%20De%20Martin%20S.%20Optimization%20of%20a%20pendant-shaped%20pegylated%20linker%20for%20antibody-drug%20conjugates.%20J%20Controll%20Release.%202024;375:74%E2%80%9389.%2010.1016/j.jconrel.2024.08.049." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Lambert JM, Berkenblit A. Antibody–drug conjugates for cancer treatment. Annu Rev Med. 2018;69(1):191–207. 10.1146/annurev-med-061516-121357.
</cite> [<a href="https://doi.org/10.1146/annurev-med-061516-121357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29414262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lambert%20JM,%20Berkenblit%20A.%20Antibody%E2%80%93drug%20conjugates%20for%20cancer%20treatment.%20Annu%20Rev%20Med.%202018;69(1):191%E2%80%93207.%2010.1146/annurev-med-061516-121357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Chari RV, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed. 2014;53(15):3796–827. 10.1002/anie.201307628.</cite> [<a href="https://doi.org/10.1002/anie.201307628" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24677743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chari%20RV,%20Miller%20ML,%20Widdison%20WC.%20Antibody%E2%80%93drug%20conjugates:%20an%20emerging%20concept%20in%20cancer%20therapy.%20Angew%20Chem%20Int%20Ed.%202014;53(15):3796%E2%80%93827.%2010.1002/anie.201307628." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114–24. 10.1021/bc0502917.
</cite> [<a href="https://doi.org/10.1021/bc0502917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16417259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Doronina%20SO,%20Mendelsohn%20BA,%20Bovee%20TD,%20Cerveny%20CG,%20Alley%20SC,%20Meyer%20DL,%20Oflazoglu%20E,%20Toki%20BE,%20Sanderson%20RJ,%20Zabinski%20RF,%20Wahl%20AF.%20Enhanced%20activity%20of%20monomethylauristatin%20F%20through%20monoclonal%20antibody%20delivery:%20effects%20of%20linker%20technology%20on%20efficacy%20and%20toxicity.%20Bioconjug%20Chem.%202006;17(1):114%E2%80%9324.%2010.1021/bc0502917." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet. 2019;394(10200):793–804. 10.1016/s0140-6736(19)31774-x.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)31774-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31478503/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chau%20CH,%20Steeg%20PS,%20Figg%20WD.%20Antibody%E2%80%93drug%20conjugates%20for%20cancer.%20Lancet.%202019;394(10200):793%E2%80%93804.%2010.1016/s0140-6736(19)31774-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Dott J, Abila B, Wuerthner JU. Current trends in the clinical development of antibody-drug conjugates in oncology. Pharm Med. 2018;32(1):259–73. 10.1007/s40290-018-0238-6.</cite> [<a href="https://scholar.google.com/scholar_lookup?Dott%20J,%20Abila%20B,%20Wuerthner%20JU.%20Current%20trends%20in%20the%20clinical%20development%20of%20antibody-drug%20conjugates%20in%20oncology.%20Pharm%20Med.%202018;32(1):259%E2%80%9373.%2010.1007/s40290-018-0238-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):1281. 10.3390/molecules22081281.
</cite> [<a href="https://doi.org/10.3390/molecules22081281" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6152078/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28763044/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20H,%20Lin%20Z,%20Arnst%20KE,%20Miller%20DD,%20Li%20W.%20Tubulin%20inhibitor-based%20antibody-drug%20conjugates%20for%20cancer%20therapy.%20Molecules.%202017;22(8):1281.%2010.3390/molecules22081281." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, Luo A, Ho PY, LeBlanc H, Blum LK, Kimmey SC. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2(1):18–33. 10.1038/s43018-020-00136-x.
</cite> [<a href="https://doi.org/10.1038/s43018-020-00136-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9012298/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35121890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ackerman%20SE,%20Pearson%20CI,%20Gregorio%20JD,%20Gonzalez%20JC,%20Kenkel%20JA,%20Hartmann%20FJ,%20Luo%20A,%20Ho%20PY,%20LeBlanc%20H,%20Blum%20LK,%20Kimmey%20SC.%20Immune-stimulating%20antibody%20conjugates%20elicit%20robust%20myeloid%20activation%20and%20durable%20antitumor%20immunity.%20Nat%20Cancer.%202021;2(1):18%E2%80%9333.%2010.1038/s43018-020-00136-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153(1):113324. 10.1016/j.biopha.2022.113324.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2022.113324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35779421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Arabi%20F,%20Mansouri%20V,%20Ahmadbeigi%20N.%20Gene%20therapy%20clinical%20trials,%20where%20do%20we%20go?%20An%20overview.%20Biomed%20Pharmacother.%202022;153(1):113324.%2010.1016/j.biopha.2022.113324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, Wang L. Effects of drug–antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody–maytansinoid conjugates. Bioconjug Chem. 2017;28(5):1371–81. 10.1021/acs.bioconjchem.7b00062.
</cite> [<a href="https://doi.org/10.1021/acs.bioconjchem.7b00062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28388844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20X,%20Ponte%20JF,%20Yoder%20NC,%20Laleau%20R,%20Coccia%20J,%20Lanieri%20L,%20Qiu%20Q,%20Wu%20R,%20Hong%20E,%20Bogalhas%20M,%20Wang%20L.%20Effects%20of%20drug%E2%80%93antibody%20ratio%20on%20pharmacokinetics,%20biodistribution,%20efficacy,%20and%20tolerability%20of%20antibody%E2%80%93maytansinoid%20conjugates.%20Bioconjug%20Chem.%202017;28(5):1371%E2%80%9381.%2010.1021/acs.bioconjchem.7b00062." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. JNCI J Natl Cancer Inst. 2019;111(6):538–49. 10.1093/jnci/djz035.
</cite> [<a href="https://doi.org/10.1093/jnci/djz035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30859213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Birrer%20MJ,%20Moore%20KN,%20Betella%20I,%20Bates%20RC.%20Antibody-drug%20conjugate-based%20therapeutics:%20state%20of%20the%20science.%20JNCI%20J%20Natl%20Cancer%20Inst.%202019;111(6):538%E2%80%9349.%2010.1093/jnci/djz035." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Marei HE, Cenciarelli C, Hasan A. Potential of antibody–drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22(1):255. 10.1186/s12935-022-02679-8.
</cite> [<a href="https://doi.org/10.1186/s12935-022-02679-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9375290/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35964048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marei%20HE,%20Cenciarelli%20C,%20Hasan%20A.%20Potential%20of%20antibody%E2%80%93drug%20conjugates%20(ADCs)%20for%20cancer%20therapy.%20Cancer%20Cell%20Int.%202022;22(1):255.%2010.1186/s12935-022-02679-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748–. 10.1016/j.addr.2007.06.008.  58.
</cite> [<a href="https://doi.org/10.1016/j.addr.2007.06.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2000329/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17659804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bareford%20LM,%20Swaan%20PW.%20Endocytic%20mechanisms%20for%20targeted%20drug%20delivery.%20Adv%20Drug%20Deliv%20Rev.%202007;59(8):748%E2%80%93.%2010.1016/j.addr.2007.06.008.%20%E2%80%8958." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J. Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Des Devel Ther. 2017;11(1):2265–76. 10.2147/DDDT.S135571.
</cite> [<a href="https://doi.org/10.2147/DDDT.S135571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5546728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28814834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalim%20M,%20Chen%20J,%20Wang%20S,%20Lin%20C,%20Ullah%20S,%20Liang%20K,%20Ding%20Q,%20Chen%20S,%20Zhan%20J.%20Intracellular%20trafficking%20of%20new%20anticancer%20therapeutics:%20antibody%E2%80%93drug%20conjugates.%20Drug%20Des%20Devel%20Ther.%202017;11(1):2265%E2%80%9376.%2010.2147/DDDT.S135571." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736–42. 10.1038/bjc.2017.367.
</cite> [<a href="https://doi.org/10.1038/bjc.2017.367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5729478/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29065110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Staudacher%20AH,%20Brown%20MP.%20Antibody%20drug%20conjugates%20and%20bystander%20killing:%20is%20antigen-dependent%20internalisation%20required?%20Br%20J%20Cancer.%202017;117(12):1736%E2%80%9342.%2010.1038/bjc.2017.367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody–drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809–17. 10.1007/s11912-022-01266-4.
</cite> [<a href="https://doi.org/10.1007/s11912-022-01266-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35305211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Giugliano%20F,%20Corti%20C,%20Tarantino%20P,%20Michelini%20F,%20Curigliano%20G.%20Bystander%20effect%20of%20antibody%E2%80%93drug%20conjugates:%20fact%20or%20fiction?%20Curr%20Oncol%20Rep.%202022;24(7):809%E2%80%9317.%2010.1007/s11912-022-01266-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Baron J, Wang ES. Gemtuzumab Ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549–59. 10.1080/17512433.2018.1478725.
</cite> [<a href="https://doi.org/10.1080/17512433.2018.1478725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6661897/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29787320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Baron%20J,%20Wang%20ES.%20Gemtuzumab%20Ozogamicin%20for%20the%20treatment%20of%20acute%20myeloid%20leukemia.%20Expert%20Rev%20Clin%20Pharmacol.%202018;11(6):549%E2%80%9359.%2010.1080/17512433.2018.1478725." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Kovtun YV, Goldmacher VS. Cell killing by antibody–drug conjugates. Cancer Lett. 2007;255(2):232–. 10.1016/j.canlet.2007.04.010.  40.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2007.04.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17553616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kovtun%20YV,%20Goldmacher%20VS.%20Cell%20killing%20by%20antibody%E2%80%93drug%20conjugates.%20Cancer%20Lett.%202007;255(2):232%E2%80%93.%2010.1016/j.canlet.2007.04.010.%20%E2%80%8940." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Nobbmann U, Connah M, Fish B, Varley P, Gee C, Mulot S, Chen J, Zhou L, Lu Y, Sheng F, Yi J. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. Biotechnol Genet Eng Rev. 2007;24(1):117–28. 10.1080/02648725.2007.10648095.
</cite> [<a href="https://doi.org/10.1080/02648725.2007.10648095" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18059629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nobbmann%20U,%20Connah%20M,%20Fish%20B,%20Varley%20P,%20Gee%20C,%20Mulot%20S,%20Chen%20J,%20Zhou%20L,%20Lu%20Y,%20Sheng%20F,%20Yi%20J.%20Dynamic%20light%20scattering%20as%20a%20relative%20tool%20for%20assessing%20the%20molecular%20integrity%20and%20stability%20of%20monoclonal%20antibodies.%20Biotechnol%20Genet%20Eng%20Rev.%202007;24(1):117%E2%80%9328.%2010.1080/02648725.2007.10648095." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Beck A, D’atri V, Ehkirch A, Fekete S, Hernandez-Alba O, Gahoual R, Leize-Wagner E, Francois Y, Guillarme D, Cianférani S. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Rev Proteomics. 2019;16(4):337–62. 10.1080/14789450.2019.1578215.
</cite> [<a href="https://doi.org/10.1080/14789450.2019.1578215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30706723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beck%20A,%20D%E2%80%99atri%20V,%20Ehkirch%20A,%20Fekete%20S,%20Hernandez-Alba%20O,%20Gahoual%20R,%20Leize-Wagner%20E,%20Francois%20Y,%20Guillarme%20D,%20Cianf%C3%A9rani%20S.%20Cutting-edge%20multi-level%20analytical%20and%20structural%20characterization%20of%20antibody-drug%20conjugates:%20present%20and%20future.%20Expert%20Rev%20Proteomics.%202019;16(4):337%E2%80%9362.%2010.1080/14789450.2019.1578215." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Chen Y. Drug-to-antibody ratio (DAR) by uv/vis spectroscopy. Antibody-Drug Conj. 2013;1045(1):267–73. 10.1007/978-1-62703-541-5_16.</cite> [<a href="https://doi.org/10.1007/978-1-62703-541-5_16" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23913153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Y.%20Drug-to-antibody%20ratio%20(DAR)%20by%20uv/vis%20spectroscopy.%20Antibody-Drug%20Conj.%202013;1045(1):267%E2%80%9373.%2010.1007/978-1-62703-541-5_16." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Andris S, Rüdt M, Rogalla J, Wendeler M, Hubbuch J. Monitoring of antibody-drug conjugation reactions with uv/vis spectroscopy. J Biotechnol. 2018;288(1):15–22. 10.1016/j.jbiotec.2018.10.003.
</cite> [<a href="https://doi.org/10.1016/j.jbiotec.2018.10.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30321572/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Andris%20S,%20R%C3%BCdt%20M,%20Rogalla%20J,%20Wendeler%20M,%20Hubbuch%20J.%20Monitoring%20of%20antibody-drug%20conjugation%20reactions%20with%20uv/vis%20spectroscopy.%20J%20Biotechnol.%202018;288(1):15%E2%80%9322.%2010.1016/j.jbiotec.2018.10.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Singh SK, Luisi DL, Pak RH. Antibody-drug conjugates: design, formulation and physicochemical stability. Pharmaceutical Res. 2015;32(1):3541-71.</cite> [<a href="https://doi.org/10.1007/s11095-015-1704-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25986175/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Singh%20SK,%20Luisi%20DL,%20Pak%20RH.%20Antibody-drug%20conjugates:%20design,%20formulation%20and%20physicochemical%20stability.%20Pharmaceutical%20Res.%202015;32(1):3541-71." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Chen T, Chen Y, Stella C, Medley CD, Gruenhagen JA, Zhang K. Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques. J Chromatogr B. 2016;1032(1):39–50. 10.1016/j.jchromb.2016.07.023.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2016.07.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27451254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20T,%20Chen%20Y,%20Stella%20C,%20Medley%20CD,%20Gruenhagen%20JA,%20Zhang%20K.%20Antibody-drug%20conjugate%20characterization%20by%20chromatographic%20and%20electrophoretic%20techniques.%20J%20Chromatogr%20B.%202016;1032(1):39%E2%80%9350.%2010.1016/j.jchromb.2016.07.023." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Bobály B, Fleury-Souverain S, Beck A, Veuthey JL, Guillarme D, Fekete S. Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates. J Pharm Biomed Anal. 2018;147(1):493–505. 10.1016/j.jpba.2017.06.022.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2017.06.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28688616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bob%C3%A1ly%20B,%20Fleury-Souverain%20S,%20Beck%20A,%20Veuthey%20JL,%20Guillarme%20D,%20Fekete%20S.%20Current%20possibilities%20of%20liquid%20chromatography%20for%20the%20characterization%20of%20antibody-drug%20conjugates.%20J%20Pharm%20Biomed%20Anal.%202018;147(1):493%E2%80%93505.%2010.1016/j.jpba.2017.06.022." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Lechner A, Giorgetti J, Gahoual R, Beck A, Leize-Wagner E, François YN. Insights from capillary electrophoresis approaches for characterization of monoclonal antibodies and antibody drug conjugates in the period 2016–2018. J Chromatogr B. 2019;1122(1):1–7. 10.1016/j.jchromb.2019.05.014.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2019.05.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31128359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lechner%20A,%20Giorgetti%20J,%20Gahoual%20R,%20Beck%20A,%20Leize-Wagner%20E,%20Fran%C3%A7ois%20YN.%20Insights%20from%20capillary%20electrophoresis%20approaches%20for%20characterization%20of%20monoclonal%20antibodies%20and%20antibody%20drug%20conjugates%20in%20the%20period%202016%E2%80%932018.%20J%20Chromatogr%20B.%202019;1122(1):1%E2%80%937.%2010.1016/j.jchromb.2019.05.014." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. InMAbs. 2011;3(2):161–72. 10.4161/mabs.3.2.14960.</cite> [<a href="https://doi.org/10.4161/mabs.3.2.14960" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3092617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21441786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wakankar%20A,%20Chen%20Y,%20Gokarn%20Y,%20Jacobson%20FS.%20Analytical%20methods%20for%20physicochemical%20characterization%20of%20antibody%20drug%20conjugates.%20InMAbs.%202011;3(2):161%E2%80%9372.%2010.4161/mabs.3.2.14960." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Matsuda Y, Leung M, Tawfiq Z, Fujii T, Mendelsohn BA. In-situ reverse phased HPLC analysis of intact antibody-drug conjugates. Anal Sci. 2021;37(8):1171–6. 10.2116/analsci.20P424.
</cite> [<a href="https://doi.org/10.2116/analsci.20P424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33518587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Matsuda%20Y,%20Leung%20M,%20Tawfiq%20Z,%20Fujii%20T,%20Mendelsohn%20BA.%20In-situ%20reverse%20phased%20HPLC%20analysis%20of%20intact%20antibody-drug%20conjugates.%20Anal%20Sci.%202021;37(8):1171%E2%80%936.%2010.2116/analsci.20P424." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Ehkirch A, d’Atri V, Rouviere F, Hernandez-Alba O, Goyon A, Colas O, Sarrut M, Beck A, Guillarme D, Heinisch S, Cianferani S. An online four-dimensional HIC× SEC-IM× MS methodology for proof-of-concept characterization of antibody-drug conjugates. Anal Chem. 2018;90(3):1578–86. 10.1021/acs.analchem.7b02110.
</cite> [<a href="https://doi.org/10.1021/acs.analchem.7b02110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29260862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ehkirch%20A,%20d%E2%80%99Atri%20V,%20Rouviere%20F,%20Hernandez-Alba%20O,%20Goyon%20A,%20Colas%20O,%20Sarrut%20M,%20Beck%20A,%20Guillarme%20D,%20Heinisch%20S,%20Cianferani%20S.%20An%20online%20four-dimensional%20HIC%C3%97%20SEC-IM%C3%97%20MS%20methodology%20for%20proof-of-concept%20characterization%20of%20antibody-drug%20conjugates.%20Anal%20Chem.%202018;90(3):1578%E2%80%9386.%2010.1021/acs.analchem.7b02110." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Torano JS, Ramautar R, de Jong G. Advances in capillary electrophoresis for the life sciences. J Chromatogr B. 2019;1118(1):116–36. 10.1016/j.jchromb.2019.04.020.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2019.04.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31035134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Torano%20JS,%20Ramautar%20R,%20de%20Jong%20G.%20Advances%20in%20capillary%20electrophoresis%20for%20the%20life%20sciences.%20J%20Chromatogr%20B.%202019;1118(1):116%E2%80%9336.%2010.1016/j.jchromb.2019.04.020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Källsten M, Hartmann R, Artemenko K, Lind SB, Lehmann F, Bergquist J. Qualitative analysis of antibody–drug conjugates (ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCs. Analyst. 2018;143(22):5487–96. 10.1039/C8AN01178H.
</cite> [<a href="https://doi.org/10.1039/c8an01178h" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30289422/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?K%C3%A4llsten%20M,%20Hartmann%20R,%20Artemenko%20K,%20Lind%20SB,%20Lehmann%20F,%20Bergquist%20J.%20Qualitative%20analysis%20of%20antibody%E2%80%93drug%20conjugates%20(ADCs):%20an%20experimental%20comparison%20of%20analytical%20techniques%20of%20cysteine-linked%20ADCs.%20Analyst.%202018;143(22):5487%E2%80%9396.%2010.1039/C8AN01178H." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Birdsall RE, Shion H, Kotch FW, Xu A, Porter TJ, Chen W. A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography. InMAbs. 2015;7(6):1036–44. 10.1080/19420862.2015.1083665.</cite> [<a href="https://doi.org/10.1080/19420862.2015.1083665" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4966495/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26305867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Birdsall%20RE,%20Shion%20H,%20Kotch%20FW,%20Xu%20A,%20Porter%20TJ,%20Chen%20W.%20A%20rapid%20on-line%20method%20for%20mass%20spectrometric%20confirmation%20of%20a%20cysteine-conjugated%20antibody-drug-conjugate%20structure%20using%20multidimensional%20chromatography.%20InMAbs.%202015;7(6):1036%E2%80%9344.%2010.1080/19420862.2015.1083665." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Saadé J, Gahoual R, Beck A, Leize-Wagner E, Francois YN. Characterization of the primary structure of cysteine-linked antibody-drug conjugates using capillary electrophoresis with mass spectrometry. Antibody-Drug Conj Methods Protocols. 2019;278(1):263–72. 10.1007/978-1-4939-9929-3_18.</cite> [<a href="https://doi.org/10.1007/978-1-4939-9929-3_18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31643063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saad%C3%A9%20J,%20Gahoual%20R,%20Beck%20A,%20Leize-Wagner%20E,%20Francois%20YN.%20Characterization%20of%20the%20primary%20structure%20of%20cysteine-linked%20antibody-drug%20conjugates%20using%20capillary%20electrophoresis%20with%20mass%20spectrometry.%20Antibody-Drug%20Conj%20Methods%20Protocols.%202019;278(1):263%E2%80%9372.%2010.1007/978-1-4939-9929-3_18." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>D’Atri V, Fekete S, Stoll D, Lauber M, Beck A, Guillarme D. Characterization of an antibody-drug conjugate by hydrophilic interaction chromatography coupled to mass spectrometry. J Chromatogr B. 2018;30(1):37–41. 10.1016/j.jchromb.2018.02.026.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2018.02.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29477065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?D%E2%80%99Atri%20V,%20Fekete%20S,%20Stoll%20D,%20Lauber%20M,%20Beck%20A,%20Guillarme%20D.%20Characterization%20of%20an%20antibody-drug%20conjugate%20by%20hydrophilic%20interaction%20chromatography%20coupled%20to%20mass%20spectrometry.%20J%20Chromatogr%20B.%202018;30(1):37%E2%80%9341.%2010.1016/j.jchromb.2018.02.026." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Vakilzadeh H, Varshosaz J, Soghrati S. Enhanced solubility and permeability of naringenin across non-everted sacs of rat small intestine by lipid nanocapsules. Recent Pat Nanotechnol. 2021;15(1):55–69. 10.2174/1872210514666200731181130.
</cite> [<a href="https://doi.org/10.2174/1872210514666200731181130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32735533/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vakilzadeh%20H,%20Varshosaz%20J,%20Soghrati%20S.%20Enhanced%20solubility%20and%20permeability%20of%20naringenin%20across%20non-everted%20sacs%20of%20rat%20small%20intestine%20by%20lipid%20nanocapsules.%20Recent%20Pat%20Nanotechnol.%202021;15(1):55%E2%80%9369.%2010.2174/1872210514666200731181130." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Gugulothu D, Khatri DK. Emerging applications of bionanomaterials in medicine and drug delivery. Bionanotechnol Emerg Appl Bionanomater. 2022;2022:129–85. 10.1016/B978-0-12-823915-5.00012-5.</cite> [<a href="https://scholar.google.com/scholar_lookup?Gugulothu%20D,%20Khatri%20DK.%20Emerging%20applications%20of%20bionanomaterials%20in%20medicine%20and%20drug%20delivery.%20Bionanotechnol%20Emerg%20Appl%20Bionanomater.%202022;2022:129%E2%80%9385.%2010.1016/B978-0-12-823915-5.00012-5." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527–37. 10.1002/ijc.22709.
</cite> [<a href="https://doi.org/10.1002/ijc.22709" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17390371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20Miyoshi%20H,%20Nakamura%20M.%20Nanomedicine%20for%20drug%20delivery%20and%20imaging:%20a%20promising%20avenue%20for%20cancer%20therapy%20and%20diagnosis%20using%20targeted%20functional%20nanoparticles.%20Int%20J%20Cancer.%202007;120(12):2527%E2%80%9337.%2010.1002/ijc.22709." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Kalhapure RS, Suleman N, Mocktar C, Seedat N, Govender T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J Pharm Sci. 2015;104(3):872–905. 10.1002/jps.24298.
</cite> [<a href="https://doi.org/10.1002/jps.24298" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25546108/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalhapure%20RS,%20Suleman%20N,%20Mocktar%20C,%20Seedat%20N,%20Govender%20T.%20Nanoengineered%20drug%20delivery%20systems%20for%20enhancing%20antibiotic%20therapy.%20J%20Pharm%20Sci.%202015;104(3):872%E2%80%93905.%2010.1002/jps.24298." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5(4):382–7. 10.1016/j.coph.2005.04.008.
</cite> [<a href="https://doi.org/10.1016/j.coph.2005.04.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15951239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Polakis%20P.%20Arming%20antibodies%20for%20cancer%20therapy.%20Curr%20Opin%20Pharmacol.%202005;5(4):382%E2%80%937.%2010.1016/j.coph.2005.04.008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Jazayeri MH, Amani H, Pourfatollah AA, Pazoki-Toroudi H, Sedighimoghaddam B. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sens Bio-sens Res. 2016;9(1):17–22. 10.1016/j.sbsr.2016.04.002.</cite> [<a href="https://scholar.google.com/scholar_lookup?Jazayeri%20MH,%20Amani%20H,%20Pourfatollah%20AA,%20Pazoki-Toroudi%20H,%20Sedighimoghaddam%20B.%20Various%20methods%20of%20gold%20nanoparticles%20(GNPs)%20conjugation%20to%20antibodies.%20Sens%20Bio-sens%20Res.%202016;9(1):17%E2%80%9322.%2010.1016/j.sbsr.2016.04.002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Goossens J, Sein H, Lu S, Radwanska M, Muyldermans S, Sterckx YG, Magez S. Functionalization of gold nanoparticles with nanobodies through physical adsorption. Anal Methods. 2017;9(23):3430–40. 10.1039/C7AY00854F.</cite> [<a href="https://scholar.google.com/scholar_lookup?Goossens%20J,%20Sein%20H,%20Lu%20S,%20Radwanska%20M,%20Muyldermans%20S,%20Sterckx%20YG,%20Magez%20S.%20Functionalization%20of%20gold%20nanoparticles%20with%20nanobodies%20through%20physical%20adsorption.%20Anal%20Methods.%202017;9(23):3430%E2%80%9340.%2010.1039/C7AY00854F." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Yao H, Jiang F, Lu A, Zhang G. Methods to design and synthesize antibody-drug conjugates (ADCs). Int J Mol Sci. 2016;17(2):194. 10.3390/ijms17020194.
</cite> [<a href="https://doi.org/10.3390/ijms17020194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4783928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26848651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yao%20H,%20Jiang%20F,%20Lu%20A,%20Zhang%20G.%20Methods%20to%20design%20and%20synthesize%20antibody-drug%20conjugates%20(ADCs).%20Int%20J%20Mol%20Sci.%202016;17(2):194.%2010.3390/ijms17020194." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Kantner T, Watts AG. Characterization of reactions between water-soluble trialkylphosphines and thiol alkylating reagents: implications for protein-conjugation reactions. Bioconjug Chem. 2016;27(10):2400–6. 10.1021/acs.bioconjchem.6b00375.
</cite> [<a href="https://doi.org/10.1021/acs.bioconjchem.6b00375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27602944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kantner%20T,%20Watts%20AG.%20Characterization%20of%20reactions%20between%20water-soluble%20trialkylphosphines%20and%20thiol%20alkylating%20reagents:%20implications%20for%20protein-conjugation%20reactions.%20Bioconjug%20Chem.%202016;27(10):2400%E2%80%936.%2010.1021/acs.bioconjchem.6b00375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Dovgan I, Kolodych S, Koniev O, Wagner A. 2-(Maleimidomethyl)-1, 3-dioxanes (MD): a serum-stable self-hydrolysable hydrophilic alternative to classical maleimide conjugation. Sci Rep. 2016;6(1):30835. 10.1038/srep30835.
</cite> [<a href="https://doi.org/10.1038/srep30835" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4977557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27501860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dovgan%20I,%20Kolodych%20S,%20Koniev%20O,%20Wagner%20A.%202-(Maleimidomethyl)-1,%203-dioxanes%20(MD):%20a%20serum-stable%20self-hydrolysable%20hydrophilic%20alternative%20to%20classical%20maleimide%20conjugation.%20Sci%20Rep.%202016;6(1):30835.%2010.1038/srep30835." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Azadbakht B, Afarideh H, Ghannadi-Maragheh M, Bahrami-Samani A, Asgari M. Preparation and evaluation of APTES-PEG coated iron oxide nanoparticles conjugated to rhenium-188 labeled rituximab. Nucl Med Biol. 2017;48(1):26–30. 10.1016/j.nucmedbio.2016.05.002.
</cite> [<a href="https://doi.org/10.1016/j.nucmedbio.2016.05.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28189044/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Azadbakht%20B,%20Afarideh%20H,%20Ghannadi-Maragheh%20M,%20Bahrami-Samani%20A,%20Asgari%20M.%20Preparation%20and%20evaluation%20of%20APTES-PEG%20coated%20iron%20oxide%20nanoparticles%20conjugated%20to%20rhenium-188%20labeled%20rituximab.%20Nucl%20Med%20Biol.%202017;48(1):26%E2%80%9330.%2010.1016/j.nucmedbio.2016.05.002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Yi G, Son J, Yoo J, Park C, Koo H. Application of click chemistry in nanoparticle modification and its targeted delivery. Biomaterials Res. 2018;22(1):13. 10.1186/s40824-018-0123-0.</cite> [<a href="https://doi.org/10.1186/s40824-018-0123-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5899385/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29686885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20G,%20Son%20J,%20Yoo%20J,%20Park%20C,%20Koo%20H.%20Application%20of%20click%20chemistry%20in%20nanoparticle%20modification%20and%20its%20targeted%20delivery.%20Biomaterials%20Res.%202018;22(1):13.%2010.1186/s40824-018-0123-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Ajith S, Almomani F, Elhissi A, Husseini GA. Nanoparticle-based materials in anticancer drug delivery: current and future prospects. Heliyon. 2023;9(11):e21227. 10.1016/j.heliyon.2023.e21227.
</cite> [<a href="https://doi.org/10.1016/j.heliyon.2023.e21227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10637937/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37954330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ajith%20S,%20Almomani%20F,%20Elhissi%20A,%20Husseini%20GA.%20Nanoparticle-based%20materials%20in%20anticancer%20drug%20delivery:%20current%20and%20future%20prospects.%20Heliyon.%202023;9(11):e21227.%2010.1016/j.heliyon.2023.e21227." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Luther DC, Huang R, Jeon T, Zhang X, Lee YW, Nagaraj H, Rotello VM. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev. 2020;156:188–213. 10.1016/j.addr.2020.06.020.
</cite> [<a href="https://doi.org/10.1016/j.addr.2020.06.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8559718/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32610061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luther%20DC,%20Huang%20R,%20Jeon%20T,%20Zhang%20X,%20Lee%20YW,%20Nagaraj%20H,%20Rotello%20VM.%20Delivery%20of%20drugs,%20proteins,%20and%20nucleic%20acids%20using%20inorganic%20nanoparticles.%20Adv%20Drug%20Deliv%20Rev.%202020;156:188%E2%80%93213.%2010.1016/j.addr.2020.06.020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Kashapov R, Ibragimova A, Pavlov R, Gabdrakhmanov D, Kashapova N, Burilova E, Zakharova L, Sinyashin O. Nanocarriers for biomedicine: from lipid formulations to inorganic and hybrid nanoparticles. Int J Mol Sci. 2021;22(13):7055. 10.3390/ijms22137055.
</cite> [<a href="https://doi.org/10.3390/ijms22137055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8269010/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34209023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kashapov%20R,%20Ibragimova%20A,%20Pavlov%20R,%20Gabdrakhmanov%20D,%20Kashapova%20N,%20Burilova%20E,%20Zakharova%20L,%20Sinyashin%20O.%20Nanocarriers%20for%20biomedicine:%20from%20lipid%20formulations%20to%20inorganic%20and%20hybrid%20nanoparticles.%20Int%20J%20Mol%20Sci.%202021;22(13):7055.%2010.3390/ijms22137055." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Kumari M, Acharya A, Krishnamurthy PT. Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics. Beilstein J Nanotechnol. 2023;14(1):912–26. 10.3762/bjnano.14.75.
</cite> [<a href="https://doi.org/10.3762/bjnano.14.75" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10494237/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37701520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kumari%20M,%20Acharya%20A,%20Krishnamurthy%20PT.%20Antibody-conjugated%20nanoparticles%20for%20target-specific%20drug%20delivery%20of%20chemotherapeutics.%20Beilstein%20J%20Nanotechnol.%202023;14(1):912%E2%80%9326.%2010.3762/bjnano.14.75." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Su D, Zhang D. Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency. Front Pharmacol. 2021;12:687926. 10.3389/fphar.2021.687926.
</cite> [<a href="https://doi.org/10.3389/fphar.2021.687926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8262647/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34248637/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Su%20D,%20Zhang%20D.%20Linker%20design%20impacts%20antibody-drug%20conjugate%20pharmacokinetics%20and%20efficacy%20via%20modulating%20the%20stability%20and%20payload%20release%20efficiency.%20Front%20Pharmacol.%202021;12:687926.%2010.3389/fphar.2021.687926." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Rodríguez-Nava C, Ortuño-Pineda C, Illades-Aguiar B, Flores-Alfaro E, Leyva-Vázquez MA, Parra-Rojas I, del Moral-Hernández O, Vences-Velázquez A, Cortés-Sarabia K, Alarcón-Romero LD. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. Biomedicines. 2023;11(6):1610. 10.3390/biomedicines11061610.
</cite> [<a href="https://doi.org/10.3390/biomedicines11061610" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10295864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37371712/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodr%C3%ADguez-Nava%20C,%20Ortu%C3%B1o-Pineda%20C,%20Illades-Aguiar%20B,%20Flores-Alfaro%20E,%20Leyva-V%C3%A1zquez%20MA,%20Parra-Rojas%20I,%20del%20Moral-Hern%C3%A1ndez%20O,%20Vences-Vel%C3%A1zquez%20A,%20Cort%C3%A9s-Sarabia%20K,%20Alarc%C3%B3n-Romero%20LD.%20Mechanisms%20of%20action%20and%20limitations%20of%20monoclonal%20antibodies%20and%20single%20chain%20fragment%20variable%20(scFv)%20in%20the%20treatment%20of%20cancer.%20Biomedicines.%202023;11(6):1610.%2010.3390/biomedicines11061610." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Zhang W, Besford QA, Christofferson AJ, Charchar P, Richardson JJ, Elbourne A, Kempe K, Hagemeyer CE, Field MR, McConville CF, Yarovsky I. Cobalt-directed assembly of antibodies onto metal–phenolic networks for enhanced particle targeting. Nano Lett. 2020;20(4):2660–6. 10.1021/acs.nanolett.0c00295.
</cite> [<a href="https://doi.org/10.1021/acs.nanolett.0c00295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32155075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20W,%20Besford%20QA,%20Christofferson%20AJ,%20Charchar%20P,%20Richardson%20JJ,%20Elbourne%20A,%20Kempe%20K,%20Hagemeyer%20CE,%20Field%20MR,%20McConville%20CF,%20Yarovsky%20I.%20Cobalt-directed%20assembly%20of%20antibodies%20onto%20metal%E2%80%93phenolic%20networks%20for%20enhanced%20particle%20targeting.%20Nano%20Lett.%202020;20(4):2660%E2%80%936.%2010.1021/acs.nanolett.0c00295." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Abdeldaim DT, Schindowski K. Fc-engineered therapeutic antibodies: recent advances and future directions. Pharmaceutics. 2023;15(10):2402. 10.3390/pharmaceutics15102402.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15102402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10610324/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37896162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Abdeldaim%20DT,%20Schindowski%20K.%20Fc-engineered%20therapeutic%20antibodies:%20recent%20advances%20and%20future%20directions.%20Pharmaceutics.%202023;15(10):2402.%2010.3390/pharmaceutics15102402." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Petrilli R, Pinheiro DP, de Cássia F, Galvão GF, Marques LG, Lopez RF, Pessoa C, Eloy JO. Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles. Curr Med Chem. 2021;28(13):2485– 520. 10.2174/0929867327666200525161359
</cite> [<a href="https://doi.org/10.2174/0929867327666200525161359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32484100/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Petrilli%20R,%20Pinheiro%20DP,%20de%20C%C3%A1ssia%20F,%20Galv%C3%A3o%20GF,%20Marques%20LG,%20Lopez%20RF,%20Pessoa%20C,%20Eloy%20JO.%20Immunoconjugates%20for%20cancer%20targeting:%20a%20review%20of%20antibody-drug%20conjugates%20and%20antibody-functionalized%20nanoparticles.%20Curr%20Med%20Chem.%202021;28(13):2485%E2%80%93%E2%80%89520.%2010.2174/0929867327666200525161359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Cao Y, Wu J, Zheng X, Lu Y, Piper JA, Lu Y, Packer NH. Assessing the activity of antibodies conjugated to upconversion nanoparticles for Immunolabeling. Anal Chim Acta. 2022;1209:339863. 10.1016/j.aca.2022.339863.
</cite> [<a href="https://doi.org/10.1016/j.aca.2022.339863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35569873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cao%20Y,%20Wu%20J,%20Zheng%20X,%20Lu%20Y,%20Piper%20JA,%20Lu%20Y,%20Packer%20NH.%20Assessing%20the%20activity%20of%20antibodies%20conjugated%20to%20upconversion%20nanoparticles%20for%20Immunolabeling.%20Anal%20Chim%20Acta.%202022;1209:339863.%2010.1016/j.aca.2022.339863." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. Int J Mol Sci. 2020;21(17):6018. 10.3390/ijms21176018.
</cite> [<a href="https://doi.org/10.3390/ijms21176018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7504566/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32825618/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Juan%20A,%20Cimas%20FJ,%20Bravo%20I,%20Pandiella%20A,%20Oca%C3%B1a%20A,%20Alonso-Moreno%20C.%20Antibody%20conjugation%20of%20nanoparticles%20as%20therapeutics%20for%20breast%20cancer%20treatment.%20Int%20J%20Mol%20Sci.%202020;21(17):6018.%2010.3390/ijms21176018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Zhou H, Fan Z, Li PY, Deng J, Arhontoulis DC, Li CY, Bowne WB, Cheng H. Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation. ACS Nano. 2018;12(10):10130–41. 10.1021/acsnano.8b04947.
</cite> [<a href="https://doi.org/10.1021/acsnano.8b04947" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6349371/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30117736/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20H,%20Fan%20Z,%20Li%20PY,%20Deng%20J,%20Arhontoulis%20DC,%20Li%20CY,%20Bowne%20WB,%20Cheng%20H.%20Dense%20and%20dynamic%20polyethylene%20glycol%20shells%20cloak%20nanoparticles%20from%20uptake%20by%20liver%20endothelial%20cells%20for%20long%20blood%20circulation.%20ACS%20Nano.%202018;12(10):10130%E2%80%9341.%2010.1021/acsnano.8b04947." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Shipunova VO, Komedchikova EN, Kotelnikova PA, Nikitin MP, Deyev SM. Targeted two-step delivery of oncotheranostic nano-PLGA for HER2-positive tumor imaging and therapy in vivo: improved effectiveness compared to one-step strategy. Pharmaceutics. 2023;15(3):833. 10.3390/pharmaceutics15030833.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15030833" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10053351/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36986694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shipunova%20VO,%20Komedchikova%20EN,%20Kotelnikova%20PA,%20Nikitin%20MP,%20Deyev%20SM.%20Targeted%20two-step%20delivery%20of%20oncotheranostic%20nano-PLGA%20for%20HER2-positive%20tumor%20imaging%20and%20therapy%20in%20vivo:%20improved%20effectiveness%20compared%20to%20one-step%20strategy.%20Pharmaceutics.%202023;15(3):833.%2010.3390/pharmaceutics15030833." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Finbloom JA, Raghavan P, Kwon M, Kharbikar BN, Yu MA, Desai TA. Codelivery of synergistic antimicrobials with polyelectrolyte nanocomplexes to treat bacterial biofilms and lung infections. Sci Adv. 2023;9(3):eade8039. 10.1126/sciadv.ade8039.
</cite> [<a href="https://doi.org/10.1126/sciadv.ade8039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9858510/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36662850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finbloom%20JA,%20Raghavan%20P,%20Kwon%20M,%20Kharbikar%20BN,%20Yu%20MA,%20Desai%20TA.%20Codelivery%20of%20synergistic%20antimicrobials%20with%20polyelectrolyte%20nanocomplexes%20to%20treat%20bacterial%20biofilms%20and%20lung%20infections.%20Sci%20Adv.%202023;9(3):eade8039.%2010.1126/sciadv.ade8039." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Discover Nano are provided here courtesy of <strong>Springer</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s11671-025-04303-w"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/11671_2025_Article_4303.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12361037/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12361037/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361037%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361037/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12361037/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12361037/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40824329/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12361037/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40824329/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12361037/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12361037/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="SIQ6GRPATpwTFdscwPwPBLhM4uAW0dAMEYr4Vdkt1nQlKpE6mfNKCE21dTOoDs9P">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
